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SUMMARY 
The use of tyrosine kinase inhibitors (TKIs) to inhibit oncogenic kinases, such as 
BCR-ABL1 and EGFR, has led to remarkable responses in patients with chronic myelogenous 
leukemia (CML) and non-small-cell lung cancer with activating mutations in EGFR (EGFR 
NSCLC). Despite the high response rates, there are still patients who do not respond 
adequately to TKIs. These findings suggest that there are additional genetic aberrations which 
could modulate a patient’s response to TKIs. Structural variations can be found in the cancer 
as well as in the normal human genome. However, their role in influencing responses to TKIs 
have not been well-established. 
 Using paired-end DNA sequencing, we discovered a novel 2,903-bp deletion 
polymorphism in intron 2 of the BIM gene. BIM is an apoptosis-inducing member of the 
BCL-2 family of proteins. Importantly, upregulation of BIM expression is required for 
sensitivity towards TKIs in CML and EGFR NSCLC. Using a minigene system, I 
demonstrated that the deletion favored the inclusion of exon 3 over exon 4, an event that could 
impair the induction of apoptosis because the apoptosis-inducing BH3 domain is found only 
in exon 4. To study the role of this deletion in mediating TKI-resistance, we have identified 
and generated CML and EGFR NSCLC cell lines that contain the deletion polymorphism. 
Compared to non-deletion containing cells, cells harboring the deletion exhibited an increased 
exon 3- to exon 4-containing BIM transcripts and decreased induction of BH3-containing BIM 
proteins after exposure to TKIs. As a result, CML and EGFR NSCLC cells harboring the 
deletion are less sensitive to TKIs. We have also demonstrated that the BH3-mimetic, ABT-
737, can sensitize deletion-containing cells to TKI-induced apoptosis. Notably, individuals 
with CML and EGFR NSCLC harboring the deletion polymorphism experienced significantly 
poorer responses to TKIs than did individuals without the polymorphism.  
Mutation analysis of the 2,903-nt deleted fragment revealed that there are multiple 
redundant cis-acting elements that repress inclusion of exon 3. In addition, I have also 
demonstrated that a 322-nt sequence at the 3’end of the deletion contains regulatory elements 
that are sufficient but not necessary for repressing exon 3 inclusion. Within this 322-nt 
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sequence, I have identified a 23-nt intronic splicing silencer that is important for exon 3 
exclusion. Furthermore, I have also identified two splicing regulators, PTBP1 and hnRNP C, 
that repress exon 3 inclusion. Functionally, downregulation of PTBP1 in K562 cells impaired 
induction of exon 4-containing splice variants and inhibited imatinib-induced apoptosis. 
Taken together, these results provide a novel mechanism by which a germline polymorphism 
mediates TKI-resistance in targeted cancer therapy and emphasize the increasing importance 
of aberrant pre-mRNA splicing in human genetic diseases. Furthermore, these findings also 
enhance our understanding of the cis-acting elements within the 2,903-nt deleted fragment 
that regulate splicing of BIM as well as defining some of the splicing factors that can 
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1.1 TYROSINE KINASES AND THEIR SIGNALING PATHWAYS 
 
 Tyrosine phosphorylation is an important type of protein modification for signal 
transduction when a cell receives extracellular stimuli such as hormones, cytokines and 
growth factors1. Tyrosine phosphorylation regulates numerous cellular processes such as cell 
proliferation, embryonic development, transcriptional activation, metabolism, cell migration, 
immune system function as well as neural transmission1; 2. The proteins that perform tyrosine 
phosphorylation are the tyrosine kinases. These kinases are enzymes that catalyze the transfer 
of the γ phosphate of adenosine triphosphate (ATP) to tyrosine residues in a protein substrate. 
Phosphorylation of tyrosine residues serves two functions in a cell. First, it enables a protein 
to regulate its enzymatic activity3. Second, tyrosine phosphorylation generates binding sites 
for proteins containing Src homology-2 (SH2) and protein tyrosine-binding (PTB) domains4.  
Two families of tyrosine kinases exist within cells. They are the receptor tyrosine  
 
kinases as well as the non-receptor tyrosine kinases. Receptor tyrosine kinases are  
 
transmembrane glycoproteins that are able to phosphorylate on tyrosine residues within the  
 
receptors and on signaling proteins that associate with the receptors. These kinases consist of  
 
a glycosylated extracellular domain that is responsible for binding to ligands, a  
 
transmembrane helix and a cytoplasmic domain that harbor tyrosine kinase activity as well as  
 
additional regulatory residues that are subjected to phosphorylation (Figure 1)1.  
 
 

















Figure 1: Domain organization of receptor tyrosine kinases. Receptor tyrosine kinases 
consist of an extracellular domain that contains a ligand-binding site, a transmembrane helix 
 3
and a cytoplasmic domain. The cytoplasmic domain contains a kinase active site that 




Because tyrosine kinases play important roles in signal transduction that mediate  
 
numerous cellular processes, the activity of tyrosine kinases are usually tightly regulated2.  
 
Activation of receptor tyrosine kinases is initiated when a ligand binds to its receptor. This  
 
process facilitates dimerization of the monomeric receptors. Because the two receptors are in  
 
close proximity, tyrosine residues on one receptor are now able to cross-phosphorylate each  
 
other. Receptor cross-phosphorylation enhances the intrinsic kinase activity of the receptor  
 
tyrosine kinase as well as generating binding sites for the recruitment of downstream  
 
signaling proteins (Figure 2)3. 
 
 

























The epidermal growth factor receptor (EGFR) is an example of a receptor tyrosine 
kinase. EGFR is activated upon binding of the epidermal growth factor to the receptor5. This 
leads to the recruitment of downstream signaling proteins such as rat sarcoma (RAS) protein 
and phosphatidylinositol 3-kinase (PI3K). Activation of these signaling proteins is essential 
for promoting cell proliferation and survival6.  
Non-receptor tyrosine kinases are another class of tyrosine kinases. Unlike receptor 
tyrosine kinases, non-receptor tyrosine kinases do not possess a transmembrane domain and 
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they are usually found in the cytoplasm7. Abelson murine leukemia viral oncogene homolog 1 
(ABL1), v-src sarcoma viral oncogene homolog (SRC) and Janus kinases (JAKs) are 
examples of non-receptor tyrosine kinases. In an inactive state, the kinase activity of ABL1 
and SRC are repressed by intramolecular interactions8. Mutating the Src homology-3 (SH3) 
domain of ABL1 has been shown to activate its kinase activity. These results suggest that the 
SH3 domain of ABL1 is able to participate in intramolecular interactions to inhibit ABL1’s 
kinase activity9. Apart from intramolecular interactions, the kinase activity of ABL1 can also 
be regulated by protein-protein interactions. For example, phosphoprotein associated with 
glycosphingolipid microdomains 1 (PAG1), is a potential inhibitor of ABL1’s kinase activity. 
PAG1 protein has been shown to interact with ABL1 and when overexpressed, it suppresses 
the kinase activity of ABL110.  
JAKs bind to cytokine receptors and have a different mode of activation when 
compared to ABL1 and SRC. JAKs are in an inactive state until cytokine receptors 
multimerize upon ligand binding, which then enable associated JAKs to cross-phosphorylate 
and become activated11. Activated JAKs also phosphorylate cytokine receptors, which create 
binding sites for the association and subsequent phosphorylation of the signal transducers and 
activators of transcription (STAT) family of transcription factors11.  
 
1.2 THE ROLE OF TYROSINE KINASES IN CANCER 
 
 Numerous studies have demonstrated that tyrosine kinases play an important role in 
the development as well as the progression of cancer2; 12; 13. Although the activity of tyrosine 
kinases are tightly regulated in normal cells, these kinases are usually targets of oncogenic 
mutations, which generate a constitutively activated tyrokine kinase that can lead to malignant 
transformation. In this thesis, I will be focusing on the role of the fusion protein, breakpoint 
cluster region (BCR)-ABL1, and activating mutations in EGFR in the development of chronic 
myelogenous leukemia (CML) and EGFR-mutated non-small-cell lung cancer (EGFR 
NSCLC), respectively.  
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The role of BCR-ABL1 in CML 
 CML is a myeloproliferative disease that is characterized by the presence of the 
fusion gene, BCR-ABL1, in primitive hematopoietic progenitors14. This fusion gene is a result 
of a reciprocal translocation between chromosome 9 and chromosome 22, which juxtaposes 
sequences from the BCR gene next to the ABL1 gene13. The resulting chromosome is known 
as the Philadelphia chromosome which can be detected by cytogenetic analysis. Experiments 
using animal models have shown that murine bone marrow cells transduced with BCR-ABL1 
retroviruses developed a myeloproliferative disorder similar to CML when these cells were 
transplanted into immunocompromised mice15. These results indicate that BCR-ABL1 is a 
potent oncogene of the hematopoietic system.  
There are two major differences between the native ABL1 protein and the BCR-
ABL1 fusion protein. Unlike the native ABL1 protein, the BCR-ABL1 fusion protein does not 
adopt a conformation that inhibit its tyrosine kinase activity. Therefore, the tyrosine kinase 
activity of BCR-ABL1 is constitutively active16. In addition, BCR-ABL1 is found 
predominantly in the cytoplasm even though it contains a nuclear localization signal. In 
contrast, the native ABL1 protein can be found in both the nucleus as well as the cytoplasm17. 
A study has shown that the localization of ABL1 in the nucleus can enhance p73-dependent 
apoptosis. These results suggest that the exclusive localization of BCR-ABL1 in the 
cytoplasm could be critical for its ability in mediating malignant transformation18. Indeed, 
blocking nuclear export of BCR-ABL1 using leptomycin B has been shown to promote the 
induction of apoptosis in CML cells17.  
 
The role of activating EGFR mutations in NSCLC 
 Lung cancer is one of the leading cause of cancer deaths worldwide19. Around 87% of 
lung cancers comprise of NSCLC. A subset of NSCLC harbor somatic mutations within the 
kinase domain of EGFR and are frequently observed in Asian women who never smoke20; 21. 
These gain-of-function mutations are usually small in-frame deletions that remove amino 
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acids 746-750 or point mutations that replace leucine with arginine at codon 858 (L858R)22; 23. 
In vitro studies have shown that both mutations lead to increased ligand-activated EGFR 
signaling as measured by autophosphorylation of tyrosine at codon 106822. Functionally, non-
transformed cells transduced with retroviruses that express mutant EGFRs can promote 
anchorage-independent growth in soft agar when compared to cells that were infected with the 
control vector24. In animal models, non-transformed cells that stably express the mutant 
EGFRs described above are capable of forming tumors in nude mice, unlike cells that express 
wildtype EGFR24. Collectively, these results indicate that activating mutations in EGFR have 
potent transforming activity.  
 
Signaling pathways activated by tyrosine kinases 
 To mediate oncogenic transformation, constitutively activated tyrosine kinases 
frequently activate signaling pathways that promote cell proliferation, inhibit apoptosis and 
enhance telomerase activity. Mutated EGFR and BCR-ABL1 activate a common series of 
signal transduction pathways, which include the: (1) mitogen-activated protein (MAP) kinase 
pathway, (2) PI3K pathway and (3) JAK-STAT pathways (Figure 3). In this section, I will 

































Figure 3: Signaling pathways activated by tyrosine kinases in cancer. MAP kinase, PI3K 
and JAK-STAT pathways are downstream pathways activated by tyrosine kinases. When 
these pathways are constitutively activated, they can mediate malignant transformation by 





MAP kinase pathway 
 The MAP kinase pathway consists of a phosphorylation cascade that regulates gene 
transcription. The phosphorylation cascade consists of three protein kinases, in which the last 
kinase in this cascade is known as the MAP kinase, an example of which is extracellular 
signal-regulated kinase (ERK) (Figure 3)25.  
 The activation of the MAP kinase pathway mediated by EGFR involves 
phosphorylation of tyrosine 1068 of EGFR. This site serves as a docking site for the SH2 
domain of the growth factor receptor-bound protein 2 (GRB2)26. GRB2 binds to the guanine 
nucleotide exchange factor, Son of Sevenless (SOS). SOS activates the RAS protein, which 
triggers the phosphorylation cascade resulting in the activation of ERK.  
 8
 In CML, BCR-ABL1 activates the MAP kinase pathway via the phosphorylated 
tyrosine 177 of BCR, which binds to GRB2. This residue performs an important role in 
leukemogenesis because mutations at tyrosine 177 can prevent its association with GRB2, as 
well as inhibits malignant transformation of primary bone marrow cultures27. Furthermore, in 
a bone marrow transplantation model, a mutation at tyrosine 177 in BCR-ABL1 can greatly 
suppressed the development of a CML-like myeloproliferative disease28.  
 
PI3K pathway 
 The PI3K pathway regulates a group of proteins that are essential for protein synthesis 
and inhibition of apoptosis. Both EGFR and BCR-ABL1 can recruit PI3K. PI3K is a lipid 
kinase that generates phosphatidylinositol-3,4,5-triphosphate (PIP3). PIP3 functions as a 
second messenger that is important for activating the serine-threonine kinase, v-akt murine 
thymoma viral oncogene homolog 1 (AKT1)29. There are two major mechanisms in which 
AKT1 can inhibit apoptotic signaling (Figure 3). First, AKT1 is able to phosphorylate the pro-
apoptotic protein, BCL-2-associated agonist of cell death (BAD). Phosphorylated BAD 
associates with the 14-3-3 proteins, which inactivate the ability of BAD to promote 
apoptosis30. Second, AKT1 can also downregulate the expression of BCL-2-like protein 11 
(BIM), another pro-apoptotic protein, by phosphorylating and inhibiting the transcription 
factor, Forkhead box O3 (FOXO3A)31. 
 The PI3K pathway is also involved in protein synthesis, which is an important process 
for cell growth and proliferation (Figure 3). This process involves activating the serine-
threonine kinase, mammalian target of rapamycin (mTOR)32. mTOR promotes translation by 
phosphorylating S6 kinases as well as the translation inhibitor, the eukaryotic translation 







As described in the previous section, activation of the STAT family of transcription 
factors requires JAKs. However, there are alternate modes of activating STAT proteins 
independent of JAKs. For instance, both EGFR and BCR-ABL1 can phosphorylate members 
of the SRC family of kinases, which then associate and activate STAT534; 35 (Figure 3). 
STAT5 plays an important role in CML because expression of a dominant negative mutant of 
STAT5 can reduce the viability of BCR-ABL1-transformed cells36. STAT5 promotes cell 
survival by transcriptionally upregulating the expression of the anti-apoptotic protein, B-cell 
lymphoma-extra large (BCL-xL)37. In addition, STAT5 can also promote telomerase activity 
by increasing the expression of human telomerase reverse transcriptase (hTERT) mRNA38; 39.  
 
1.3 TYROSINE KINASE INHIBITORS AS THERAPEUTIC AGENTS IN CANCER  
 
 Because numerous studies have demonstrated that oncogenic kinases, such as BCR-
ABL1 and EGFR, play an important role in malignant transformation, a rational approach to 
treat kinase-driven cancers is to develop targeted therapies against the kinases driving these 
diseases. Small molecule tyrosine kinase inhibitors (TKIs) and monoclonal antibodies are two 
classes of drugs that have been developed to target oncogenic kinases. In this thesis, I will be 
focusing only on TKIs for the treatment of CML and EGFR NSCLC. At the beginning of this 
section, I will introduce the concept of “oncogene addiction”, which is an important concept 
that could explain why CML and EGFR NSCLC respond to TKIs. Next, I will discuss the 
differences between TKIs and conventional chemotherapy in terms of cytotoxicity. This will 
be followed by a discussion on the mechanism of action, adverse and therapeutic effects of 
two TKIs, namely imatinib and gefitinib. Finally, I will end this section with a discussion on 






 Cancer cells are frequently characterized with multiple gene mutations, chromosomal 
structural variations, epigenetic abnormalities as well as changes in gene expression  
profile40; 41. Therefore, it appears that multiple cancer-specific genes have to be targeted in 
order to inhibit the growth and the proliferation of cancer cells. However, there are examples 
in animal models suggesting that targeting a single important oncogene is sufficient to cause 
tumor regression. In some instances, it has been shown in a murine model of T-cell 
lymphomas driven by the MYC oncogene that inactivation of MYC alone is sufficient to cause 
tumor regression, even though cancer is a multistage process that involve the accumulation of 
multiple transforming mutations42.   
 These results indicate that for some cancers, such as CML, the malignant cells are 
highly dependent on the expression of a single oncogene for survival. This phenomenon is 
termed as “oncogene addiction”43. Oncogene addiction can be exploited in cancer therapy by 
designing drugs that are specific against proteins that the tumor is “addicted” to. The use of 
TKIs for the treatment of CML and EGFR NSCLC are excellent examples of exploiting 
oncogene addiction in cancer therapy because these cancers are dependent on oncogenic 
kinases (BCR-ABL1 and EGFR) for survival. Indeed, in vitro studies using cancer cell lines 
have shown that TKIs, when used as single agents, have antitumor activities against CML and 
EGFR NSCLC44; 45.  
 
TKIs versus conventional chemotherapy 
 Conventional chemotherapy is a form of cancer therapy that involves the use of 
cytotoxic drugs such as doxorubicin and cisplatin. These cytotoxic drugs are effective against 
rapidly dividing cells, which is a characteristic of cancer cells. However, there are non-
diseased cells within the body that are rapidly dividing as well such as cells in the 
gastrointestinal tract, the bone marrow and the hair follicles. As a result, patients who receive 
conventional chemotherapy usually experience adverse side effects such as vomiting, hair loss 
and myelosuppression46. In contrast, targeted therapies, such as the use of TKIs, are specific 
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against a particular protein that the tumor cells are “addicted” to when compared to non-
malignant cells. Thus, TKIs are generally specific towards kinase-driven cancers with the 
potential for fewer adverse effects when compared to patients treated with conventional 
chemotherapy46. 
 
The use of imatinib for the treatment of CML 
Imatinib, also known as Gleevec, is a small molecule inhibitor of ABL1 and BCR-
ABL1. This drug competes with ATP for the ATP binding site of BCR-ABL1, and hence, 
inhibits the phosphorylation of BCR-ABL1’s substrates13. Strikingly, the use of imatinib to 
treat chronic phase (early stage) CML yielded remarkable responses. For instance, in a 
randomized clinical trial known as the IRIS (International Randomized Study of Interferon 
and STI571) study, an overall survival of 88% was observed among patients treated with 
imatinib, which was higher than the survival rate of 43% when patients were treated with 
other drugs47; 48. Side effects related to the use of imatinib are relatively tolerable which 
include fatigue, skin rashes and diarrhoea49. The mild side effects observed in patients were 
surprising given the fact that imatinib also inhibits other kinases, and therefore, could 
potentially lead to adverse side effects in patients50. Furthermore, mice with the c-abl gene 
ablated had abnormal T- and B-cells development and died a few weeks after they were 
born51. The low frequency of adverse side effects could be due to several reasons. First, 
although the dose of imatinib used in patients may be sufficient to inhibit BCR-ABL1, it may 
not be enough to inhibit the native ABL1 protein52. Second, it is also possible that the plasma 
concentration of imatinib may not be sufficient to inhibit the native ABL1 protein completely 
i.e. there is still residual ABL1 activity to allow normal cell function to persist53.  
 
The use of gefitinib for the treatment of EGFR NSCLC 
 Gefitinib and erlotinib are two EGFR TKIs that are available in the clinic for the 
treatment of EGFR NSCLC. In this thesis, I will be focusing on the use of gefitinib for the 
treatment of EGFR NSCLC. Gefitinib suppresses signaling pathways downststream of EGFR 
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by competing reversibly with ATP for the ATP-binding domain on EGFR54. Experiments 
performed on xenograft models showed that gefitinib was able to potentiate the antitumoral 
effects of several cytotoxic drugs55. Furthermore, gefitinib was also well-tolerated when it was 
administered to healthy volunteers56. These early findings suggest that gefitinib may be 
effective for treating patients with NSCLC, a disease that has a poor prognosis even with 
conventional chemotherapy. Surprisingly, phase III clinical trials in unselected patients with 
NSCLC indicated that there was no significant improvement in survival when gefitinib was 
used together with standard chemotherapy57; 58. Interestingly, these studies revealed that 
approximately 10% of unselected NSCLC patients had a dramatic response to gefitinib. 
Further analysis revealed that patients who responded to gefitinib harbor small deletions 
within the kinase domain or a recurrent L858R substitution. Both mutations increase EGFR 
signaling as well as promote sensitivity towards gefitinib in vitro22. These results suggest that 
tumors harboring activating mutations in EGFR could be more dependent on EGFR signaling, 
and hence, more sensitive to inhibition of EGFR. Indeed, in the Iressa Pan-Asia Study, 
NSCLC patients with activating mutations in EGFR had a longer progression free survival 
(PFS) with gefitinib (9.5 months) when compared to patients who were treated with 
carboplatin and paclitaxel (6.3 months). Notably, gefitinib does not appear to be more 
superior compared to carboplatin and paclitaxel among the group of patients that were not 
selected for EGFR mutations59. Collectively, these findings indicate that therapeutic decisions 
can be personalized according to the molecular phenotype of the patient’s cancer.  
 
1.4 CLINICAL RESISTANCE TO TYROSINE KINASE INHIBITORS 
 
Although the use of imatinib for the treatment of chronic phase CML has been a huge 
clinical success, there are still drawbacks to this therapy. For instance, there are approximately 
20% of CML patients who do not respond well to imatinib and are at risk of disease 
progression60. Drug resistance is the main reason for the poor response to imatinib. Next, 
while imatinib is effective in controlling chronic phase CML, it does not seem to eradicate the 
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disease entirely in most patients. Only about 10% of chronic phase patients achieve a 
complete molecular remission (no detectable BCR-ABL1 transcripts), and even among these 
patients, half will relapse following therapy cessation61. This phenomenon is thought to be due 
to the persistence of a small number of CML stem cells that are able to survive imatinib 
treatment62. Similarly, not all patients with EGFR NSCLC responded to gefitinib. The 
response rate to gefitinib is around 62 to 73%63; 64. Among patients who respond to gefitinib, 
the mean duration of response is around 6 to 8 months65; 66. The transient response to gefitinib 
is also due to drug resistance, which I will discuss in greater detail in the next section.  
 Resistance can be characterized by the time of onset. Primary resistance refers to the 
failure to respond to initial therapy. In contrast, secondary resistance, also known as acquired 
resistance, refers to patients who respond to TKIs at the start of therapy, but who eventually 
lose their response67; 68.  
 Resistance can also be defined according to the clinical responses observed and then 
compared against a series of guidelines established by clinicians. For example in NSCLC, 
tumor response to gefitinib can be assessed by imaging the tumor at regular intervals and then 
use of the RECIST (Response Evaluation Criteria In Solid Tumors) criteria to evaluate the 
tumor response69. For CML, resistance can be classified according to the European 
LeukemiaNet criteria70. Based on this criteria, resistance to TKIs in CML can be further 
categorized into two groups, “warning” and “failure”. Patients who fail to respond are less 
likely to benefit if they continue using TKIs and should seek alternative therapies, while 
patients classified under “warning” could still benefit from TKIs, but they require more 
frequent monitoring70. 
 
1.5 MOLECULAR BASIS OF RESISTANCE TO TYROSINE KINASE INHIBITORS 
 
 Generally, the mechanisms of resistance to TKIs can be grouped into two main 
categories. First, resistance mechanisms can be oncogenic kinase-dependent such as mutations 
in the kinase domain that reduce the binding efficiency of TKIs, or overexpression of the 
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oncogenic kinases. Second, factors mediating resistance to TKIs can also be oncogenic 
kinase-independent. These include the tumor microenvironment, differential activity of drug 
influx and efflux pumps, and reactivation of pro-survival signaling pathways. Here, I will be 
reviewing some of the mechanisms that have been described to mediate TKI-resistance in 
CML and EGFR NSCLC.  
 
Mutation and overexpression of oncogenic tyrosine kinases 
 The development of mutations in the kinase domain of BCR-ABL1 and EGFR are 
commonly observed in CML and EGFR NSCLC cells that are resistant to TKIs. These 
mutations are associated with secondary (acquired) resistance to TKIs71; 72. In CML, mutations 
in the BCR-ABL1 kinase domain can already be found in patients who have yet to receive 
treatment with TKIs and therefore, it is hypothesized that TKIs exert a selection pressure 
which allow resistant subclones harboring BCR-ABL1 kinase domain mutations that have 
arise stochastically to grow more rapidly than cells that are sensitive to TKIs73.  
 Mutations in the kinase domain of BCR-ABL1 and EGFR usually occur around the 
ATP-binding cleft, resulting in a poorer interaction between the TKIs and the kinases13; 74. 
Examples of mutations around the ATP-binding cleft that resulted in TKI-resistance include 
the Y253F and E255K BCR-ABL1 mutants14 as well as the T790M EGFR mutant75. To 
overcome resistance associated with mutations in the kinase domain, second generation TKIs 
have been developed that can inhibit the kinase activity of these mutants. For instance, 
dasatinib and nilotinib are active against most BCR-ABL1 mutants, and are currently approved 
for use in the clinic76; 77. Neratinib is a second generation EGFR TKI for NSCLC, which has 
been shown to reduce the viability of NSCLC cell lines harboring the T790M mutation78. 
 Overexpression of the BCR-ABL1 protein is also observed in a subset of CML 
patients who are resistant to imatinib79. This contributes to imatinib resistance because the 
therapeutic dose of the drug is unable to inhibit increased levels of the BCR-ABL1 protein. 
There are several mechanisms resulting in an increased expression of BCR-ABL1 such as 
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BCR-ABL1 gene amplification as well as aberrant transcriptional and posttranscriptional 
regulation of BCR-ABL179; 80; 81.  
 
Reactivation of pro-survival signaling pathways 
 Interestingly, a significant proportion of individuals with clinical resistance to TKIs in 
CML or EGFR NSCLC do not harbor mutations in BCR-ABL1 or EGFR. Reactivation of pro-
survival signaling pathways is a mechanism which can enable these tumor cells to survive 
even though BCR-ABL1 or EGFR has been effectively inhibited. In CML, treatment with 
imatinib has been shown to enhance MAP kinase signaling in CML progenitor cells even 
though the kinase activity of BCR-ABL1 has been suppressed. These observations suggest 
that the failure to completely eliminate CML progenitors by imatinib treatment alone may be 
attributed by enhance MAP kinase signaling. Indeed, pharmacologic inhibition of MAP 
kinase signaling, together with imatinib treatment, has been shown to reduce the number of 
CML progenitors dramatically82.  
 Genetic alterations or overexpression of the SRC family of non-receptor tyrosine 
kinases, such as SRC and v-yes-1 Yamaguchi sarcoma viral related oncogene homolog 
(LYN), are frequently observed in cancers83. Constitutive activation of LYN has been 
observed in several CML patients who do not harbor mutations in BCR-ABL184. Furthermore, 
increased expression of LYN is correlated with disease progression as well as resistance to 
imatinib85. More importantly, reducing the expression of LYN using small interfering RNAs 
(siRNAs) can promote the cell-killing effects of imatinib86. Taken together, these results 
suggest that LYN may activate pro-survival signaling pathways such that both BCR-ABL1 
and LYN have to be inhibited to overcome imatinib resistance associated with constitutive 
LYN activation. 
 Amplification of the gene encoding the hepatocyte growth factor receptor (MET) has 
been observed in EGFR NSCLC tumor samples as well as in a EGFR NSCLC cell line that is 
resistant to gefitinib87. Amplification of MET enhances gefitinib resistance by activating the 
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PI3K signaling pathway. Notably, suppression of MET signaling enhanced the growth 
inhibitory effects of gefitinib87.  
 
Tumor microenvironment 
 The interplay between the tumor cells and the microenvironment play important roles 
in mediating drug resistance and tumor progression88. In solid tumors, tumor hypoxia is a 
condition where cancer cells experience low oxygen levels89. This condition arises due to 
rapid proliferation of tumor cells, which eventually exceed their oxygen supply. Structural 
changes to the tumor microvessels can also contribute to tumor hypoxia as well89. Hypoxia-
inducible factor-1α is an important transcription factor that is upregulated under hypoxia, and 
it induces the transcription of genes that are essential for enhancing cell viability, 
angiogenesis and drug resistance90. In EGFR NSCLC, hypoxia is found to play a role in 
promoting resistance to gefitinib by increasing the expression of transforming growth factor-
α91.  
 Intriguingly, the bone marrow is also hypoxic92. Since hematopoietic stem cells reside 
in the bone marrow, it has been proposed that hypoxia plays a role in the maintenance of 
hematopoietic stem cells. Indeed, in vitro experiments have demonstrated that immature 
progenitors survive better in hypoxia than in normoxia93. In CML, incubation of CML cells in 
hypoxia promotes the growth of leukemic stem cells that do not express BCR-ABL1 proteins 
even though BCR-ABL1 transcripts could still be detected. These hypoxia-selected cells are no 
longer dependent on BCR-ABL1 signaling, and therefore, they are resistant to imatinib 
treatment94; 95. These results are consistent with the observation that although imatinib elicits a 
remarkable response in individuals with chronic phase CML, most individuals are usually not 
cured as there are a small number of leukemic stem cells that are still present after imatinib 
treatment.  
 The bone marrow microenvironment also contain stromal cells that protect leukemic 
stem cells from TKIs. Indeed, coculture with bone marrow mesenchymal stromal cells protect 
CML stem cells from imatinib-induced apoptosis as well as maintaining CML stem cells 
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repopulating ability via a mechanism that is dependent on β-catenin-mediated signaling96. 
Collectively, these results indicate that signals from stromal cells within the bone marrow 
microenvironment can protect CML stem cells from TKIs.  
 
Drug influx and efflux pumps 
 Intracellular drug availability can modulate an individual’s response to TKIs. The 
transport of TKIs into and out of the cells is tightly regulated by drug influx and efflux 
pumps97. In CML, the human organic cation transporter type 1 (hOCT1), a protein that 
regulates drug uptake, has been studied for its role in imatinib resistance. Using an inhibitor 
that is specific for hOCT1, a group has shown that hOCT1 is required for the transport of 
imatinib into the cells, suggesting that decreased expression of hOCT1 may lead to imatinib 
resistance by lowering intracellular imatinib levels98.  
 Aberrant expression of drug efflux pumps can also lead to TKI-resistance by actively 
transporting the drug out of cells. Using a CML cell line that is resistant to imatinib, another 
group has observed an upregulation of the drug efflux pump, multidrug resistance protein 1 
(MDR1)99. Mechanistically, depleting MDR1 protein levels enhance the intracellular 
concentration of imatinib as well as promoting imatinib-induced cell death100. These results 
suggest that the upregulation of MDR1 can protect CML cells from imatinib by transporting 
the drug out of cells.  
 The role of the drug exporter, ATP-binding cassette, sub-family G (WHITE), member 
2 (ABCG2), has been investigated for its role in mediating gefitinib resistance. Increased 
expression of ABCG2 has been observed in a gefitinib-resistant EGFR NSCLC cell line, 
which is associated with lower levels of mitoxantrone in the cells when compared to a 
gefitinib-sensitve EGFR NSCLC cell line101. Functionally, forced expression of ABCG2 
protected an EGFR-dependent epidermoid carcinoma cell line from the cell-killing effects of 
gefitinib102. Taken together, these results suggest that increased expression of ABCG2 could 




1.6 BIOMARKERS THAT PREDICT RESPONSE TO TYROSINE KINASE 
INHIBITORS 
 
 Since a proportion of CML and EGFR NSCLC patients display signs of resistance 
towards TKIs, there is a need to develop biomarkers that can predict response to TKIs. This 
would enable a better management of these diseases because an alternative treatment plan, 
such as increasing the dose of TKIs or the use of combination therapy, can be implemented 
for these high-risk patients to prevent the emergence of drug resistance or disease progression. 
There are currently very few validated biomarkers that can accurately predict response to 
TKIs at the point of diagnosis. Ideally, a good biomarker should fulfill the following criteria. 
First, an ideal biomarker should have a detection method that is sensitive, specific, and 
reproducible. Second, a proposed biomarker for TKI-resistance should be independently 
validated in a prospective study with a large sample size. Finally, functional studies should 
also be performed to provide a mechanistic rationale for the use of a proposed biomarker for 
predicting response to TKIs. In this section, I will review biomarkers that predict the response 
of CML and EGFR NSCLC patients to TKIs. At the end of this section, I will discuss the role 
of germline polymorphisms to predict sensitivity towards TKIs. 
 
Biomarkers to predict response to TKIs in CML patients 
 The clinical Sokal score is a scoring system that is used to predict for TKI-resistance 
in CML patients at the point of diagnosis103; 104. This scoring system is based on clinical and 
laboratory features, such as the percentage of blast cells, the size of the spleen as well as the 
platelet count, to assess a CML patient’s risk of developing TKI-resistance103. Although the 
clinical Sokal score is still in use by clinicians, it is not a reliable indicator of a patient’s 
response towards TKIs because a study has shown that a large proportion of CML patients 
with a high Sokal risk (69 to 84%) actually responded well to therapy with imatinib105. The 
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failure to account for the molecular features of the disease could explain why the Sokal score 
is not a useful indicator for predicting outcome to TKIs.  
 The clinical relevance of the expression levels of drug influx and efflux pumps have 
also been assessed in population studies. Earlier studies have shown that increased expression 
of the drug efflux pump, MDR1, can protect CML cells from the cell-killing effects of 
imatinib in vitro99; 100. However, several clinical studies failed to establish a relationship 
between expression levels of MDR1 and clinical response to imatinib106; 107. These results 
suggest that the expression levels of MDR1 may not be an appropriate marker to predict for 
response towards TKIs in CML. In contrast, the expression levels of the drug influx pump, 
hOCT1, may have some prognostic value. A study conducted by Wang et al. (2007) observed 
that CML patients with high hOCT1 mRNA levels, before imatinib treatment, had a higher 
complete cytogenetic response rates and overall survival. They have also demonstrated that 
forced expression of hOCT1 in CML cells promoted imatinib uptake108. Together, these 
findings suggest that the expression levels of hOCT1 before treatment may be a useful 
indicator to predict response to imatinib.  
 The use of a single biomarker to predict for therapeutic response may be hampered by 
the lack of sensitivity and specificity. Therefore, it may be prudent to utilize a panel of 
biomarkers to predict for response towards TKIs. Recently, a study conducted by McWeeney 
et al. (2010) discovered a minimal gene expression signature comprising 75 transcripts that 
could predict major cytogenetic responses in imatinib-treated CML patients with an accuracy 
rate of more than 80%. Within this group of transcripts that could predict for imatinib 
response, more than 60% are known to be regulated by β-catenin, suggesting that β-catenin 
could play an important role in mediating resistance towards imatinib105. However, a pitfall of 
this study is that the functional roles of these 75 transcripts in mediating imatinib resistance 





Biomarkers to predict response to TKIs in EGFR NSCLC patients 
 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), a member of the 
RAS family of proteins, is a signaling protein downstream of EGFR. KRAS is also a proto-
oncogene that plays an important role in the development of NSCLC. Approximately 15-30% 
of NSCLC cases harbor activating mutations in KRAS109. Interestingly, activating mutations in 
KRAS and EGFR occur in a mutually exclusive manner, suggesting that KRAS and EGFR 
activate similar pro-survival signaling pathways110; 111. Numerous clinical studies have 
reported that the presence of activating KRAS mutations in NSCLC is associated with a poorer 
response to EGFR TKIs111; 112. These observations indicate that assessing KRAS mutation 
status may be useful for determining whether a patient should receive EGFR TKIs.  
 Studies have shown that amplification of the proto-oncogene MET can induce 
resistance towards EGFR TKIs by activating PI3K87. These findings suggest that MET 
amplification could predict for a poorer response towards EGFR TKIs. However, MET 
amplification is not frequently observed in untreated patients, occurring in less than 5% of 
untreated NSCLC patients113. However, around 20% of NSCLC patients with acquired 
resistance to EGFR TKIs, harbor an increased MET copy number change87; 113. These results 
suggest that MET amplification is associated with acquired resistance to EGFR TKIs, and 
therefore, it may not be a useful biomarker to predict response to EGFR TKIs at the point of 
diagnosis.  
 
The use of germline polymorphisms to predict sensitivity to TKIs 
 The use of TKIs to treat kinase-driven cancers has resulted in high response rates. 
However, response heterogeneity is a pertinent issue that clinicians are facing. Response 
heterogeneity includes significant differences in the degree of initial response, duration of 
response, as well as overall survival114. Response heterogeneity can be partially explained by 
polymorphic variants. Usually, these polymorphic variants modulate sensitivity to TKIs by 
affecting pharmacokinetics, such as drug absorption, drug distribution, metabolism and 
elimination115. In support of the notion that polymorphic variants can affect response 
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heterogeneity, a recent work has described an abundance of rare functional germline variants 
in drug target genes116. 
Currently, there is limited information regarding the role of germline polymorphisms 
in mediating TKI-resistance. Most studies focused on polymorphisms that are found on drug 
efflux pumps. Dulucq et al. (2008) have studied several single nucleotide polymorphisms 
(SNPs) of MDR1 and their association with achieving major molecular responses in CML 
patients treated with imatinib117. For the 1236 C>T SNP, they found that patients homozygous 
for the T allele achieved major molecular responses more frequently when compared to other 
genotypes (85% versus 47.7%; p=0.003). In contrast, for the 2677 G>T/A SNP, the presence 
of the G allele was associated with a poorer response to imatinib117.  
 The 421 C>A SNP of ABCG2 has also been studied for its role in the accumulation of 
gefitinib in the cell. A study conducted by Li et al. (2007) showed that accumulation of 
gefitinib was higher among patients heterozygous for this SNP118. Collectively, these results 
suggest that patients heterozygous for the 421 C>A SNP of ABCG2 may have a better 
response to gefitinib when compared to patients homozygous for the C allele.  
 The first intron of EGFR contains a polymorphic region with extensive CA 
dinucleotide repeats. Experimental studies demonstrated that the transcription activity of 
EGFR decreases with increasing number of CA repeats in the first intron119. Several clinical 
studies observed that EGFR NSCLC patients harboring short CA repeats have a better 
response to gefitinib and a longer overall and progression free survival120; 121. However, the 
results from these studies were controversial because two other studies failed to observe any 
association between the number of CA repeats and clinical outcome122; 123.  
 Taken together, these studies demonstrated that there is potential in utilizing germline 
polymorphisms to predict response towards TKIs. However, most of these polymorphic 
biomarkers are not used in the clinics yet because of controversial findings. These 
controversial findings could be accounted for by the retrospective nature of most clinical 
studies as well as the small sample size. Therefore, it is important to validate these 
polymorphisms in a prospective study using a larger sample size. Next, it is also important to 
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provide a mechanistic rationale for utilizing these polymorphisms as prognostic markers by 
performing functional studies. However, it is challenging to provide direct evidence to prove 
that polymorphic variants occurring in the non-coding regions of the gene, including introns, 
can mediate resistance towards TKIs. To address this problem, tools such as zinc-finger 
nucleases (ZFNs) could be employed to modify the genome. This would enable the generation 
of isogenic cell lines for assessing whether a particular polymorphism could mediate TKI-
resistance.  
 
1.7 THE ANALYSIS OF GENOME STRUCTURAL VARIATIONS USING NEXT-
GENERATION SEQUENCING OF PAIRED-END TAGS 
 
 Genomic alterations are important features of human cancers and they are believed to 
be important drivers of cancer development and disease progression124. Genomic alterations in 
the cancer genome include point mutations as well as structural variations. Feuk et al. (2006) 
define structural variations as genomic aberrations that involve portions of DNA that are 
greater than 1-kb125. Examples of structural variations include deletions, insertions, 
amplifications, inversions and translocations. Interestingly, structural variations are also 
present in the normal human genome125. It has been hypothesized that polymorphic structural 
variations, together with SNPs, can affect an individual’s risk for developing certain diseases 
and influence response to drugs124. 
 Somatic structural variations can drive tumorigenesis in several ways. Firstly, a 
deletion or a duplication event involving an entire gene can lead to a change in gene 
expression in a dose-dependent manner. Secondly, structural variations, such as deletions, can 
affect gene expression if they overlap with cis-regulatory elements that modulate transcription 
or pre-mRNA splicing. Finally, inversions and translocations could generate fusion proteins 
that could promote cancer development125.  
 There are several tools to study genome structural variations. Fluorescence in situ 
hybridization is one of the earliest cytogenetic methods that is developed to study structural 
 23
variations. However, this technique could not analyze structural variations in a high 
throughput manner. Array-based comparative genome hybridization (array-CGH) approaches 
are tools that can analyse structural variations in a high throughput manner. However, array-
CGH cannot identify balanced structural variations such as balanced translocations126. Recent 
developments in next generation DNA sequencing technologies make it possible to 
characterize most structural variations, including balanced translocations, using genomic 
DNA-paired-end tags (DNA-PET) sequencing and mapping approaches. To generate DNA-
PETs, the genomic DNA is initially sheared into fragments. Subsequently, fragments of 
specific sizes are purified. Short tag signatures of around 20- to 30-bp are extracted from the 
two ends of the DNA fragments, and then the tags are paired together for sequencing analysis. 
The sequences obtained are mapped to the reference genome to infer the size of the DNA 
fragments. Most of the DNA-PET sequences are in agreement with the reference genome with 
the correct orientation and the appropriate size range. DNA-PETs with mapping orientation 
and distance that are not in agreement with the reference genome can be used to assess where 
the breakpoints of structural variations are located126. 
 Several groups have employed the DNA-PET sequencing approach to identify 
genomic rearrangements in cancer. Campbell et al. (2008) employed short DNA fragments 
between 200- to 500-bp for mapping structural variations and identified more than 400 
structural variations in two lung cancer cell lines. However, due to the use of short DNA 
fragments for mapping, they could not unravel large insertions. Furthermore, it is not easy to 
discover structural variations in repetitive regions because the short DNA fragments could not 
span repeats127. Hillmer et al. (2011) used 10-kb genomic DNA fragments to identify 
structural variations in fifteen cancer genomes. The use of a larger DNA fragment can 
overcome the disadvantages of using short DNA fragments because they are able to identify 
structural variations within repetitive regions128. With the various modifications made to the 
DNA-PET sequencing strategy, this technique has become a useful and a powerful method for 
characterizing structural variations in the genome.  
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1.8 AIM OF STUDY 
 
 A proportion of CML patients are resistant to TKIs in the absence of BCR-ABL1 
mutations and BCR-ABL1 overexpression. Without an effective biomarker to stratify these 
patients for closer monitoring and to guide therapy, these individuals are at risk of disease 
progression and will sucuumb to the disease eventually. We hypothesized that the acquisition 
of genetic abnormalities, such as structural variations, could mediate TKI-resistance in these 
patients. Therefore, the main aim of this study is to employ DNA-PET sequencing to identify 
structural variations that are associated with TKI-resistance in CML. A candidate structural 
variation will be identified by DNA-PET and the association of this structural variation with 
TKI-resistance will be validated in a larger CML cohort. I will be performing functional 
studies to characterize the function, as well as the mechanism in which this structural variation 
mediates TKI-resistance by performing assays in primary CML cells and cell lines. 
Furthermore, I will also select an appropriate drug that is relevant to the mechanism causing 
TKI-resistance and assess whether co-treatment with TKIs can overcome resistance associated 
with the candidate structural variation. At the molecular level, CML and EGFR NSCLC are 
similar diseases because they are both driven by oncogenic tyrosine kinases. Hence, I will also 
be assessing whether the candidate structural variation also play an important role in 
















Programmed cell death, also known as apoptosis, functions as an important barrier to 
prevent the development of cancer129. There are two major signaling pathways controlling the 
induction of apoptosis, namely the intrinsic and the extrinsic pathway. In this thesis, I will be 
focusing primarily on the induction of apoptosis via the intrinsic pathway. 
 The intrinsic pathway, also known as mitochondrion-initiated apoptosis, is regulated 
by the B-cell lymphoma 2 (BCL-2) family of proteins130. The BCL-2 family comprises of 
proteins that are either pro- or anti-apoptotic. The anti-apoptotic members of the BCL-2 
family such as BCL-2, BCL-xL and myeloid cell leukemia sequence 1 (MCL-1) contain four 
BCL-2 homology (BH) domains which are essential for cell survival131. BCL-2-associated X 
(BAX) and  BCL-2 homologous antagonist/killer (BAK) are pro-apoptotic proteins harboring 
three BH domains. These proteins are important for permeabilization of the mitochondrial 
outer membrane for releasing cytochrome c to activate caspases132 (Figure 4). Activation of 
BAK and BAX are suppressed by the anti-apoptotic proteins, BCL-2, BCL-xL and MCL-1132. 
The BH3-only proteins, which function to initiate apoptosis by associating with the anti-
apoptotic members of the BCL-2 family, are activated in a stimulus-dependent manner131 
(Figure 4). Members of this class of pro-apoptotic proteins include BIM, BAD, phorbol-12-
myristate-13-acetate-induced protein 1 (NOXA) and p53 upregulated modulator of apoptosis 
(PUMA). Among these BH3-only proteins, BIM and PUMA have also been shown to interact 














Figure 4: The intrinsic pathway of apoptosis. BAX and BAK are effectors of the intrinsic 
pathway of apoptosis that are required for the permeabilization of the mitochondrial outer 
membrane. This result in the release of cytochrome c, followed by the activation of caspases. 
The anti-apoptotic members of the BCL-2 family, BCL-2, BCL-xL and MCL-1, inhibit the 
release of cytochrome c by interacting with BAK and BAX. The BH3-only proteins (BIM, 
NOXA, BAD and PUMA) are selectively activated depending on the type of apoptotic 
stimulus received. The BH3-only proteins trigger apoptosis by sequestering the anti-apoptotic 




 The BH3-only protein, BIM, is upregulated upon treatment with TKIs in CML and 
EGFR NSCLC134; 135; 136; 137; 138. The upregulation of BIM occurs in a transcriptional and a 
post-translational manner. Transcriptional upregulation of BIM is a result of inactivation of 
the PI3K signaling, which leads to the activation of the transcription factor, FOXO3A31. Post-
translational stabilization of the BIM protein is mediated through inhibition of the ERK 
pathway, which targets BIM for proteosomal degradation by phosphorylation139. Knockdown 
of BIM expression has been shown to suppress TKI-induced apoptosis in CML and EGFR 
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NSCLC cells, indicating that upregulation of BIM is critical for the induction of TKI-induced 
apoptosis134; 135; 136; 137; 138. 
 Here, I will be describing the use of DNA-PET to discover a novel common deletion 
polymorphism in the BIM gene that is present in clinical samples derived from patients with 
CML who are resistant to TKIs. In the later part of the thesis, I will be characterizing the 
function and mechanism by which the BIM deletion polymorphism mediates resistance to 
TKIs in CML and EGFR NSCLC.  
 
2.2 IDENTIFICATION OF A 2,903-BP DELETION POLYMORPHISM IN THE 
SECOND INTRON OF THE BIM GENE 
 
 We chose four CML patient samples harboring the Philadelphia chromosome, a  
 
remission sample (P440) obtained from a patient who responded well to TKIs (P145) and the  
 
K562 CML cell line for DNA-PET analysis (Table 1). These clinical samples are composed  
 
of patients from chronic phase and myeloid blast crisis. Both patients in myeloid blast crisis  
 
(P022 and P098) and one of the chronic phase patients (P308) exhibited clinical TKI- 
 
resistance. In addition, one of the blast crisis samples had additional cytogenetic  
 
abnormalities, which served as an important validation for the capability of the DNA-PET  
 
technology to discover structural variations. Critically, the clinical samples that were obtained  
 
from patients who are resistant to TKIs are not known to harbor mutations in the BCR-ABL1  
 
kinase domain that could not be inhibited by imatinib or the second generation BCR-ABL1  
 
kinase inhibitor, dasatinib. Accordingly, structural variations that were detected in the  
 
resistant samples may contribute to TKI-resistance in a BCR-ABL1-independent manner. 
 
We also included a remission sample derived from a patient with a major molecular remission  
 
and the K562 CML cell line as a negative and a positive control respectively, for the  
 














P145* Chronic Yes No No No 
P440* Remission No No No No 
P308 Chronic Yes No Yes No 
P098 Blast Yes No Yes Y253F 
P022 Blast Yes Yes Yes No 




Table 1:  Clinical features of the CML patient samples and the K562 CML cell line used  
for DNA-PET analysis. [* represent clinical samples obtained from the same patient at  





 Using DNA-PET, we found a novel 2,903-bp deletion in the second intron of the BIM 
gene that was present only in the CML samples that were resistant to TKIs (P022, P098 and 
P308). The deletion encompass chromosome 2: 111,599,666 to 111,602,568 (Figure 5a,b). 
We were keen to study this structural variation because numerous groups have reported that 
upregulation of BIM is required for imatinib-induced apoptosis in CML cells134; 135; 136.  
 We have also validated the presence of the deletion by performing PCR using primers  
 
that flanked the region that was deleted. PCR analysis revealed that the deletion was indeed  
 
present only in our clinical samples that were derived from patients that are resistant to TKIs  
 
(Figure 5c). The results also showed that the three resistant samples are heterozygous carriers  
 
for the deletion because both the full-length PCR product of 4,226-bp and the truncated  
 
product of 1,323-bp were amplified (Figure 5c). The truncated PCR products from these  
 
three resistant samples were also sent for sequencing to identify the breakpoints. Strikingly,  
 
all three resistant samples had the identical 2,903-bp deletion, which suggests that the deletion  
 









Figure 5: A 2,903-bp deletion polymorphism in the second intron of the BIM gene is 
detected in TKI-resistant CML samples. (a) Genome browser view of the DNA-PET  
analysis from the five clinical samples and the K562 cell line. * represent clinical samples  
obtained from the same patient at chronic phase (P145) and at remission (P440). The red  
tracks indicate the number of sequenced concordant PETs that map to the region. The number  
of concordant PETs around BIM intron 2 is lower in the resistant samples, suggesting that  
there is a deletion present. Mapping region of discordant PETs is indicated by the burgundy  
and pink arrowheads. The green line connecting the arrowheads and the vertical dashed lines  
represent the region that is deleted. (b) Schematic outline of the deletion. The deletion is  
represented as a dark blue rectangle, whereas the grey rectangles represent the flanking  
intronic sequences. Sequences within the deletion are typed in blue. (c) PCR of the genomic  
DNA from the five clinical samples and the K562 CML cell line using primers that flanked  
the deletion. In the absence of the deletion, a product of 4,226-bp will be amplified. A shorter  
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product of 1,323-bp is amplified if the deletion is present. PCR products were resolved in a 
1% agarose gel. (a, b and c are from Ng et al., Nature Medicine 18:521-528, 2012)140. Note:  
DNA-PET sequencing and identification of structural variations were performed by Dr  
Axel Hillmer and staff from the Genome Institute of Singapore, Singapore. PCR validation  





To confirm that the deletion is a germline variant, we screened populations of 
different ethnicity to assess the frequency of the deletion (Table 2). We observed that the 
deletion is present commonly in normal individuals from East-Asian populations. The 
deletion is present in 12.3% (75/608) of healthy Chinese individuals, 6.8% (41/600) of Malay 
individuals, 0.5% (3/600) of Indian individuals and 14.3% (5/35) of Japanese HapMap 
individuals (Table 2). Intriguingly, this deletion allele is absent in healthy German 
individuals, as well as European and African HapMap individuals (Table 2).  
  
 Genotype 







Chinese (n=608) 533 72 3 0.123 0.064 
Malay (n=600) 559 41 0 0.068 0.034 
Indian (n=600) 597 3 0 0.005 0.0025 
German (n=595) 595 0 0 0 0 
HapMap: Chinese (n=39) 31 8 0 0.205 0.103 
                Japanese (n=35) 30 4 1 0.143 0.086 
                African (n=60) 60 0 0 0 0 




Table 2: Frequencies of the BIM deletion polymorphism in various ethnic populations.  
Genomic DNA samples were amplified using primers that flanked the deletion to screen for  
the BIM deletion polymorphism. The resulting PCR products were resolved in a 1% agarose  
gel. (From Ng et al., Nature Medicine 18:521-528, 2012)140. Note: Assessing the frequencies  
of the BIM deletion polymorphism in various ethnic populations were performed by Dr  







2.3 EFFECTS OF THE BIM DELETION POLYMORPHISM ON GENE 
EXPRESSION 
 
 Since our  preliminary analysis on the five clinical samples suggests that the BIM 
deletion polymorphism could be associated with TKI-resistance, I next sought to characterize 
the functional effects of the BIM deletion polymorphism.   
 The BIM gene comprises of five exons (E1 to E5) (Figure 6). Pre-mRNA splicing of  
 
the primary transcript can give rise to the three pre-dominant BIM isoforms namely: BIMEL,  
 
BIML and BIMS. The BH3 domain of BIM is found exclusively in exon 4. This domain is  
 
essential for the induction of apoptosis because it interacts with pro-survival proteins such as  
 
BCL-2141. A hydrophobic domain is present in exon 5 and it has been proposed that the  
 
hydrophobic domain is required for full apoptotic activity of BIM142. Another BIM isoform  
 
known as BIMγ, is a result of alternative splicing that leads to the inclusion of exon 3. BIMγ  
 
terminates at exon 3 because exon 3 contains a stop codon as well as a polyadenylation signal.  
 
In addition, exon 3 also lacks a 5’ splice site to enable splicing with exon 4. As a result, the  
 
alternative splicing of exon 3 and exon 4 is mutually exclusive. Since the BIMγ protein lacks  
 
the BH3 and the hydrophobic domain present in exon 4 and exon 5 respectively, we  
 









BIM E1 E2A E2B E2C E3 E4 E5
BH3
Stop
BIMEL E1 E2A E2B E2C E4 E5
BIML E1 E2A E2C E4 E5
BIMS E1 E2A E4 E5









Figure 6: Genomic organization of the BIM gene. The BIM gene is made up of five exons  
(E1, E2, E3, E4, E5). Various BIM isoforms (BIMEL, BIML, BIMS  and BIMγ) can arise as a  
result of alternative splicing. The BH3 domain and the hydrophobic domain are found in exon  
4 and exon 5, respectively. Exon 3 and exon 5 also contain a stop codon and a  
polyadenylation (polyA) signal. A dynein binding domain (DBD) is present in exon 2C. The  
2,903-bp intronic deletion is represented by the red line. The diagram is not drawn to scale. 




 Detailed inspection of the BIM deletion polymorphism revealed that the deletion is 
close to exon 3 (107-bp upstream of exon 3) (Figure 5b). Because introns contain cis-
regulatory elements that can promote or suppress assembly of the spliceosomes143 and that 
these regulatory elements can be found at a distance of more than 200-bp from the nearest 
exon144, our findings suggest that the polymorphic fragment may contain regulatory elements 
that could affect the mutually exclusive splicing of exons 3 and exon 4.  
 To test this hypothesis, I generated two minigene plasmids to assess whether splicing 
of BIM exons 3 and 4 are affected when the 2,903-bp intronic sequence has been removed. 
These minigene reporters are generated in the context of the pI-12 plasmid (a kind gift from 
Professor Mariano Garcia-Blanco) which contains two adenovirus exonic sequences (U and 
D) (Figure 7a). The non-deletion (WT) minigene was created by cloning BIM exon 3, exon 4, 
the 2,903-bp deleted region as well as some additional intronic sequences to ensure proper 
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splicing of exons 3 and 4. Notably, exon 4 was “fused” with the adenovirus exonic sequence 
D, which contains a polyadenylation signal for proper transcription termination and 3’end 
formation. The deletion (DEL) minigene is similar to the WT minigene except that it has the 
2,903-bp intronic sequence removed (Figure 7a). Because splicing of exon 3 and exon 4 are 
mutually exclusive, we expect the minigenes to generate two transcripts, U-E3 and U-E4-D 
(Figure 7a).  
K562 cells were nucleofected with these minigenes and RNA was extracted from 
these cells 24 hours later. To distinguish transcripts that were generated by the minigenes 
from the endogenous BIM transcripts, one of the primers used for real-time RT-PCR analysis 
is complementary to the adenovirus exonic sequence U. Our results showed that the DEL 
minigene favored inclusion of exon 3 over exon 4 by at least 5-fold when compared to the WT 
minigene in K562 cells (Figure 7b). I have also introduced these minigenes into the KCL22 
CML cell line as well. Consistent with the earlier findings in K562 cells, I also found that the 
DEL minigene in KCL22 cells also favored the inclusion of exon 3 over exon 4 when 
compared to cells that were nucleofected with the WT minigene (Figure 7b). Collectively, 
these data strongly argue for the hypothesis that the 2,903-bp intronic sequence contains 
regulatory elements that repress inclusion of BIM exon 3. When this sequence is removed, 
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Figure 7: The presence of the BIM deletion polymorphism favors splicing to BIM exon 3  
over exon 4. (a) Schematics of the WT and the DEL minigene for assessing whether the BIM  
deletion polymorphism affects the splicing of BIM exons 3 and 4. (b) K562 and KCL22 cells  
were nucleofected with 1 μg of minigene constructs. RNA was isolated from these cells 24  
hours later and real-time RT-PCR analysis was performed to assess the expression of  
minigene products containing exon 3 over exon 4. The results were normalized to the 
adenovirus exonic sequence (U). Experiments were performed in triplicates and data is 
shown as mean ± standard error of the mean. *p < 0.05, **p < 0.01 compared to cells  
nucleofected with the WT minigene using Student’s t-test. (a and b are from Ng et al., Nature 




To determine whether primary CML cells with the deletion also favor splicing to BIM  
 
exon 3 over exon 4, I analyzed primary CML cells from individuals with and without the BIM  
 
deletion polymorphism by real-time RT-PCR. Exon-specific primers were used to assess the  
 
relative expression of endogenous BIM transcripts containing exon 3 over exon 4. To  
 
determine the expression of total BIM transcripts, I have also performed real-time RT-PCR  
 
analysis using primers that are specific for exon 2A since exon 2A is present in all BIM  
 
isoforms. I observed that patients harboring the BIM deletion polymorphism expressed  
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significantly higher levels of exon 3-containing BIM transcripts when compared to patients  
 
without the deletion (Figure 8). In contrast, expression of exon 4-containing transcripts was  
 
lower among carriers of the BIM deletion polymorphism. Consistent with the minigene  
 
experiment, the ratio of exon 3- to exon 4-containing transcripts was also significantly  
 
elevated among patients harboring the BIM deletion polymorphism (Figure 8). Importantly,  
 
expression of total BIM transcripts remained unchanged between these two groups of patients,  
 








Figure 8: CML patients with the BIM deletion polymorphism exhibit an increased exon  
3- to exon 4-containing BIM transcripts. Expression levels of exon-specific BIM transcripts  
in 23 CML patient samples with (carriers; n=12) and without (WT; n=11) the BIM deletion  
polymorphism were determined using real-time RT-PCR. The expression levels of exon 3-  
and exon 4-containing transcripts were normalized to E2A whereas the expression levels of  
total BIM transcripts were normalized to β-actin. One homozygous carrier for the deletion  
polymorphism was identified and its transcript levels were indicated in green. Experiments  
were performed in duplicates and data is shown as mean ± standard error of the mean.  
Statistical significance was determined using the Wilcoxon rank sum test. (From Ng et al.,  
Nature Medicine 18:521-528, 2012)140. 
 
 It is possible that the increased exon 3- to exon 4-containing BIM transcripts observed  
earlier is a lineage-dependent effect. To exclude this possibility, I have also analyzed a group  
 
of lymphoblastoid cell lines derived from healthy HapMap individuals with (n=4) and without  
 
(n=3) the deletion polymorphism. Consistent with the earlier results, I observed that samples  
 
containing the deletion polymorphism also exhibited an increased exon 3- to exon 4- 
 
containing BIM transcripts when compared to samples that did not contain the deletion,  
 
indicating that the effects mediated by the polymorphism were not dependent on cell lineage  
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(Figure 9). Crucially, the enhanced exon 3- to exon 4-containing transcripts also appears to  
 
occur in a polymorphism-dosage dependent manner as well because the sample that was  
 
derived from a homozygous carrier of the deletion has the greatest expression of exon 3- 
 
containing transcripts over exon 4. In addition, there was also no significant difference in the  
 
expression of total BIM transcripts between the carriers and the non-carriers of the deletion  
 
(Figure 9). Taken together, based on the minigene analysis and the expression of exon 3- and  
 
exon 4-containing BIM transcripts in primary cells, the results strongly argue for the  
 
hypothesis that cis-regulatory elements that repress inclusion of exon 3 are present in the 2.9- 
 
kb deleted fragment. Consequently, individuals who harbor the deletion express more exon 3- 
 
containing BIM transcripts over exon 4 when compared to non-carriers. Furthermore, the  
 
results also suggest that general transcription of the BIM gene is unlikely to be affected by the  
 








Figure 9: Normal HapMap individuals with the BIM deletion polymorphism also  
showed an increased exon 3- to exon 4-containing BIM transcripts. Expression levels of  
exon-specific BIM transcripts in 7 non-diseased HapMap individuals with (carriers; n=4) and  
without (WT; n=3) the BIM deletion polymorphism were determined using real-time RT- 
PCR. The expression levels of exon 3- and exon 4-containing transcripts were normalized to  
E2A whereas the expression levels of total BIM transcripts were normalized to β-actin. One  
homozygous carrier for the deletion polymorphism was identified and its transcripts levels  
were indicated in green. Experiments were performed in triplicates. (From Ng et al., Nature 




 We have also considered two other effects of the BIM deletion polymorphism on gene 
expression. Several groups have reported that genetic mutations can lead to aberrant splicing 
of pre-mRNAs by creating or activating cryptic splice sites145; 146; 147. As a result, aberrantly 
 38 
spliced novel transcripts could be expressed and these novel transcripts may play a role in 
disease pathophysiology. To address whether the BIM deletion polymorphism leads to the 
expression of aberrantly spliced novel transcripts, I have performed RT-PCR and sequenced 
all the exon 3- and exon 4-containing transcripts from three clinical samples obtained from 
CML patients harboring the BIM deletion polymorphism (P022, P098, P308) as well as the 
K562 cell line, which do not contain the deletion. Two different pairs of primers were used to 
amplify exon 3- and exon 4-containing transcripts since these exons are mutually exclusive. 
Using agarose gel electrophoresis to resolve the PCR products, I observed that the separation 
patterns of the PCR products were similar when I compared the three clinical samples with 
the K562 cell line (Figure 10). All observable PCR products were sent for sequencing. Apart 
from the three pre-dominant BIM splice variants (BIMEL, BIML, BIMS ), there were also other 
BIM transcripts expressed as well such as BIMα1.. Importantly, the three clinical samples that 
harbor the deletion did not express any novel BIM splice variants when I compared cDNAs 
from these three clinical samples with the K562 cell line. In addition, I did not observe any 
non-silent mutations in any of the cDNAs as well. Intriguingly, I have also discovered a novel 
exon 3-containing BIM variant that consists of exon 1-exon 2A-exon 2B-exon 2C-exon 3. 
Taken together, these observations indicate that the BIM deletion polymorphism does not lead 






                                          














Figure 10: The BIM deletion polymorphism does not generate novel BIM transcripts.  
RT-PCR was performed on RNAs from three CML patients harboring the BIM deletion  
polymorphism (P022, P098, P308) and the K562 CML cell line. Two differerent pairs of  
primers were used for PCR to amplify cDNAs encoding BIM because BIM exon 3 and exon 4  
are mutually exclusive. The resultant PCR products were resolved in a 2% agarose gel.  
The nomenclature for identifying the various BIM splice variants has been described  
previously148. (From Ng et al., Nature Medicine 18:521-528, 2012)140. 
 
 Several groups have reported that enhancers promoting gene transcription can be  
 
found in the introns149; 150. We hypothesized that the deleted fragment may contain enhancer  
 
activity which can promote BIM transcription when CML cells were treated with imatinib.  
 
Therefore, transcription of the BIM gene may be suppressed when the 2.9-kb sequence is  
 
removed. To test this hypothesis, we cloned the 2,903-bp fragment into the pGL4 vector  
 
downstream of the firefly luciferase reporter (Fluc) gene. This vector also contains the BIM  
 
promoter (Pro) as well (Figure 11). Subsequently, we nucleofected K562 cells with the  
 
reporter constructs and treated these cells with DMSO or imatinib for 15 hours before  
 
measuring the relative luciferase activity. A 1.52-fold increase in luciferase activity was  
 
observed when cells were treated with imatinib in the presence of a reporter construct that did  
 
not contain the 2,903-bp intronic sequence (Figure 11). This result is consistent with prior  
 
data demonstrating an increasing in BIM transcription upon treatment with imatinib in CML  
 




reporter did not further enhance luciferase activity when K562 cells were treated with imatinib  
 
(Figure 11). Taken together, these results indicate that the 2,903-bp intronic sequence does not  
 
contain enhancer activity, which is consistent with earlier results showing that the deletion has  
 


















Figure 11: The 2,903-bp intronic sequence does not contain enhancer activity. The 2,903- 
bp intronic sequence was cloned downstream of the Fluc reporter gene, whereas the BIM  
promoter (Pro) was cloned upstream of the Fluc reporter. K562 cells were nucleofected with 
the indicated reporter constructs. 24 hours after nucleofection, these cells were treated with  
either DMSO or imatinib. The relative luciferase activity was measured 15 hours later.  
Experiments were performed in triplicates and data is shown as mean ± standard error of the  
mean. Note: Luciferase assay was performed by Dr Ng King Pan from Duke-NUS Graduate  






 Using DNA-PET, we discovered a novel 2,903-bp deletion polymorphism in the 
second intron of the BIM gene that was present in our samples that were derived from CML 
patients who are resistant to TKIs. This deletion polymorphism is present commonly in non-
diseased individuals from East-Asian populations but it is absent in healthy European and 
African individuals. Minigene analysis showed that the 2,903-bp deletion contains cis-
regulatory elements that repress inclusion of BIM exon 3. Consequently, individuals who 
harbor the deletion express more exon 3-containing BIM transcripts over exon 4 when 
compared to non-carriers. I have also demonstrated that the BIM deletion polymorphism does 
 41
not generate novel BIM transcripts and it also does not contain enhancer activity that promote 










Effects of aberrant splicing mediated by the BIM deletion 






I have shown previously that individuals who harbor the BIM deletion polymorphism 
express more exon 3-containing BIM transcripts over exon 4 when compared to non-carriers. 
In this chapter, I will investigate the effects of aberrant splicing mediated by the BIM deletion 
polymorphism on TKI-resistance in cancer.  
 
3.2 THE BIM DELETION POLYMORPHISM MEDIATES RESISTANCE TO 
TYROSINE KINASE INHIBITORS IN CHRONIC MYELOGENOUS LEUKEMIA 
 
Since the BH3 domain, which is important for the induction of apoptosis, is found 
only in exon 4 of BIM, the results which I have observed earlier suggest a novel mechanism of 
resistance to TKIs. In this model, when CML cells are exposed to TKIs, cells that harbor the 
BIM deletion polymorphism would favor the expression of exon 3-containing transcripts over 
transcripts containing exon 4 as a result of aberrant pre-mRNA splicing. Consequently, these 
cells harboring the polymorphism would express insufficient levels of BH3-containing BIM 
proteins to induce apoptosis. To test this hypothesis, I screened a panel of CML cell lines 
using PCR to identify cell line(s) that harbor the BIM deletion polymorphism. Among the 
CML cell lines that I screened, the KCL22 cell line was the only cell line that harbor the BIM 
deletion polymorphism (Figure 12). KCL22 is also heterozygous for the deletion because both 
the full-length and the truncated PCR products were amplified.  
 44 








































Figure 12: Identification of the KCL22 cell line that harbors the BIM deletion  
polymorphism. Genomic DNA was isolated from a panel of nine CML lines. Among them,  
seven cell lines were derived from individuals from East Asia. PCR was performed using  
primers that flanked the region that is deleted. A truncated product of 1,323-bp would be  
amplified if there is an allele harboring the deletion. PCR products were resolved in a 1%  
agarose gel. (From Ng et al., Nature Medicine 18:521-528, 2012)140. 
 
 Next, I performed real-time RT-PCR analysis to assess the expression of exon 3- to 
exon 4-containing BIM transcripts in KCL22 cells and compared the expression with two 
other CML cell lines that do not contain the BIM deletion polymorphism (K562 and KYO-1). 
Consistent with my earlier findings in primary CML patient samples, the KCL22 cell line has 
a significantly higher exon 3- to exon 4-containing BIM transcripts when compared to K562 
and KYO-1 cells (Figure 13a).  
 To investigate whether the induction of exon 4-containing BIM transcripts and protein  
 
isoforms are impaired by the deletion polymorphism, I have also subjected KCL22, K562 and  
 
KYO-1 cells to imatinib treatment and measured transcript and protein levels of exon 4- 
 
containing BIM. I observed that KCL22 cells exhibited a decreased induction of exon 4-  
 
containing transcripts (Figure 13b) as well as lower levels of BH3-containing BIM isoforms  
 
after imatinib treatment when compared to K562 and KYO-1 cells (Figure 13c). To exclude  
 
the possibility that impaired induction of BH3-containing BIM proteins is a result of  
 
ineffective inhibition of BCR-ABL1 by imatinib in KCL22 cells, I have also assessed the  
 
protein levels of phosphorylated v-crk sarcoma virus CT10 oncogene homolog (avian)-like  
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(pCrkL) and phosphorylated ribosomal protein S6 (pRPS6), which are downstream targets of  
 
BCR-ABL1. I observed that in KCL22 cells, expression of both pCrkL as well as pRPS6  
 
decreased to a similar extent after treatment with imatinib when compared with K562 and  
 
KYO-1 cells (Figure 13c). This indicated that BCR-ABL1 was effectively inhibited in KCL22  
 







































































Figure 13: The KCL22 cell line expresses lower levels of exon 4-containing BIM  
transcripts and BH3-containing BIM isoforms after imatinib treatment when compared  
to K562 and KYO-1 cells. (a) RNA isolated from K562, KCL22 and KYO-1 cells was  
subjected to real-time RT-PCR analysis to assess the expression of exon 3- to exon 4- 
containing BIM transcripts. Experiments were performed in triplicates and data is shown as  
mean ± standard error of the mean. *p < 0.05 compared to KCL22 using Student’s t-test. (b)  
K562, KCL22 and KYO-1 cells were treated with 1 μM imatinib. RNA was extracted from  
these cells after 12 hours and real-time RT-PCR was performed to assess the expression levels  
of exon 4-containing BIM transcripts. Experiments were performed in triplicates and data is  
shown as mean ± standard error of the mean relative to untreated K562 cells. *p < 0.05,  
**p < 0.01 compared to KCL22 cells treated with imatinib using Student’s t-test. (c) Western 
blot showing impaired upregulation of BH3-containing BIM proteins in KCL22 cells even 
when signaling pathways downstream of BCR-ABL1 were effectively inhibited by imatinib.  
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Western blot image shown is a representative image from three independent experiments. (a, b  
and c are from Ng et al., Nature Medicine 18:521-528, 2012)140. 
 
 
 Since induction of exon 4-containing BIM transcripts and BH3-containing BIM  
 
proteins were impaired in the KCL22 cell line after treatment with imatinib, I hypothesized  
 
that the KCL22 cell line is more resistant to imatinib when compared to other CML cell lines  
 
that do not harbor the BIM deletion polymorphism. Trypan blue exclusion assay was  
 
performed on four CML cell lines, including KCL22. These cells were exposed to 1 μM  
 
imatinib and the number of viable cells was determined every 24 hours over a period of 120  
 
hours (5 days). At the end of the experiment, KCL22 was found to be the most resistant cell  
 
line to imatinib with a 2.5-fold increase in the number of viable cells relative to the total  
 
number of viable cells at the beginning of the experiment (Figure 14a). The other three  
 
remaining non-deletion-containing CML cell lines (K562, KYO-1 and NCO2) were more  
 
sensitive to imatinib because their number of viable cells decreased by at least 40% at the end  
 
of the experiment (Figure 14a). Western blot was also performed after treating these CML cell  
 
lines with imatinib to assess the expression of cleaved caspase 3, a marker for apoptosis. I  
 
observed greater expression of cleaved caspase 3 when K562 and KYO-1 cells were exposed  
 
to imatinib when compared to the KCL22 cell line (Figure 14b). Taken together, these results  
 
demonstrated that KCL22 cells are more resistant to imatinib-induced apoptosis when  
 
compared to CML cell lines that do not harbor the BIM deletion polymorphism. These data  
 
are consistent with previous studies demonstrating that the KCL22 cell line is resistant to  
 
imatinib99; 151, although the mechanism of resistance was not previously known. We  
 
hypothesized that one of the mechanisms of TKI-resistance in KCL22 could be due to  
 



















































Figure 14: The KCL22 cell line is resistant to imatinib-induced apoptosis. (a) 500,000  
K562, KCL22, KYO-1 and NCO2 cells were exposed to 1 μM imatinib over a five-day  
period. A trypan blue count was performed every 24 hours to assess the number of viable cells  
remaining. Experiments were performed in triplicates and data is shown as mean ± standard  
error of the mean. (b) K562, KCL22 and KYO-1 cells were treated with (1 μM) or without  
imatinib. Whole cell lysates were obtained from these cells after 24 hours. Western blot was  
performed to assess the expression of full-length and cleaved caspase 3.  Western blot image  
shown is a representative image from three independent experiments. (b is from Ng et al., 





 The results obtained so far indicated that induction of BH3-containing BIM proteins  
 
is impaired in KCL22 (Figure 13), which is associated with resistance to imatinib in  
 
these cells (Figure 14). To establish that decreased expression of exon 4- containing BIM  
 
transcripts is indeed responsible for resistance towards imatinib in KCL22 cells, I have  
 
overexpressed exon 3- and exon 4-containing transcripts in KCL22 and assessed the  
 
induction of apoptosis by cleaved caspase 3 expression (Figure 15a) and Annexin V staining  
 
(Figure 15b). Strikingly, substantial cleavage of poly (ADP-ribose) polymerase (PARP) and  
 
caspase 3 were observed after expressing BH3-containing BIM isoforms (BIMEL, BIML,  
 
BIMS) (Figure 15a). In constrast, there was little PARP and caspase 3 cleavage when BIMγ  
 
was re-expressed in KCL22 cells. Consistent with these observations, there was a 2-fold  
 
increase in the number of Annexin V positive-KCL22 cells compared to vector control cells  
 
after re-expressing BIML and BIMS (Figure 15b). However, there was no significant increase  
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in the number of Annexin V positive cells when I overexpressed KCL22 cells with BIMγ.  
 
Surprisingly, even though these cells were nucleofected with equal amount of plasmids,  
 
expression of  BIMγ was very weak when compared to the exogenous BH3-containing BIM  
 


















































Figure 15: KCL22 cells are sensitive to increased expression of exon 4-containing BIM  
isoforms. (a) KCL22 cells were nucleofected with 5 μg of expression plasmids containing  
BIMEL, BIML, BIMS or BIMγ cDNAs that were tagged with the FLAG epitope. 24 hours later,  
whole cell lysates were obtained from these cells and Western blot was performed to  
determine the expression of PARP, cleaved caspase 3 and FLAG-tagged BIM proteins.  
Western blot image shown is a representative image from three independent experiments. (b)  
KCL22 cells were nucleofected in the same manner that was described above. 24 hours later,  
Annexin V staining was performed on these cells and the number of Annexin V positive cells  
were determined using a flow cytometer. Experiments were performed in triplicates and data  
is shown as mean ± standard error of the mean relative to cells nucleofected with the vector  
control plasmid. **p < 0.01 compared to KCL22 cells nucleofected with vector control  





To determine whether BIMγ has a shorter half-life when compared to BH3 (exon 4)- 
 
containing BIM isoforms, I nucleofected K562 cells with an expression plasmid expressing  
 
either FLAG-tagged BIML or FLAG-tagged BIMγ. I chose to express BIML in this experiment  
 
because the N-terminal portion of BIML and BIMγ are identical (exon 1-exon 2A-exon 2C).  
 
24 hours post-nucleofection, I added cycloheximide into these cells to inhibit protein  
 
translation and harvest cells at various time points to assess the expression of exogenous  
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BIM proteins by Western blot. Using the expression of β-catenin as a positive control for a  
 
protein with a short half-life, I observed that BIMγ has a much shorter half-life ( < 0.5 hours)  
 














Figure 16: The BIMγ protein is more unstable then BIML. K562 cells were nucleofected  
with plasmids expressing either FLAG-tagged BIML or BIMγ. 24 hours later, these cells were  
treated with cycloheximide. Whole cell lysates were obtained from these cells at various time  
points and Western blot was performed to assess the expression of β-catenin and FLAG- 
tagged BIM. Western blot image shown is a representative image from three independent  
experiments. (From Ng et al., Nature Medicine 18:521-528, 2012)140. 
 
Apart from having a decreased expression of exon 4-containing BIM transcripts, the  
 
KCL22 cell line has an elevated expression of BIM transcripts containing exon 3. To exclude  
 
the possibility that increased expression of exon 3-containing BIM transcripts plays a role in  
 
promoting imatinib resistance, I assessed the induction of imatinib-induced apoptosis after  
 
using siRNAs to deplete exon 3-containing BIM transcripts in KCL22 cells. Using two  
 
independent siRNAs that were specific against BIM exon 3, I was able to achieve at least  
 
50% reduction in the expression of exon 3-containing BIM transcripts (Figure 17a). However,  
 
decreased expression of exon 3-containing BIM transcripts did not enhance imatinib-induced  
 
apoptosis in KCL22 cells when compared to cells that were nucleofected with control siRNAs  
 
(Figure 17b).  
 
 Taken together, the results strongly suggest that elevated expression of exon 3- 
 
containing BIM transcripts does not promote or protect KCL22 cells from imatinib-induced  
 
apoptosis. This is probably due to the fact that the BIMγ protein is relatively unstable when  
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compared to BH3-containing BIM proteins such as BIML. Instead, it is the decreased  
 
induction of BH3 (exon 4)-containing BIM isoforms, probably due to aberrant pre-mRNA  
 









































































Figure 17: Decreased expression of exon 3-containing BIM transcripts does not enhance  
imatinib-induced apoptosis in KCL22 cells. (a) KCL22 cells were nucleofected with 300  
nM of control or BIM exon 3-specific siRNAs. 48 hours post-nucleofection, RNA was  
isolated from these cells and real-time RT-PCR was performed to determine the relative  
expression of exon 3-containing BIM transcripts. Experiments were performed in triplicates  
and data is shown as mean ± standard error of the mean relative to cells that were not  
nucleofected. “U” represents cells that were not nucleofected. **p < 0.01 compared to KCL22  
cells nucleofected with control siRNA using Student’s t-test. (b) KCL22 cells were  
nucleofected with 300 nM of control or BIM exon 3-specific siRNAs. 24 hours post- 
nucleofection, these cells were treated with 1 μM imatinib and Annexin V staining was  
performed 48 hours later to determine the number of apoptotic cells. “U” represents cells that  
were not nucleofected. Experiments were performed in triplicates and data is shown as mean  
± standard error of the mean. (a and b are from Ng et al., Nature Medicine 18:521-528,  
2012)140.  
 
 ABT-737 is a BH3-mimetic that functions as a small molecule inhibitor of BCL-2 and 
BCL-xL152. Previously, it has been reported that co-treatment with ABT-737 is able to 
overcome single-agent imatinib resistance caused by loss of BIM or increased expression of 
BCL-2134. Since impaired upregulation of BH3-containing BIM isoforms is responsible for 
imatinib resistance in KCL22, I asked whether ABT-737 could enhance imatinib-induced 
apoptosis in these cells. In this experiment, I treated KCL22 cells with imatinib alone or in 
combination with ABT-737. 48 hours later, whole cell lysates were obtained from these cells 
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and Western blot was performed to assess the expression of cleaved caspase 3. As a positive 
control to show that imatinib as a single agent can induce apoptosis in non-deletion-
containing CML cells, I have also performed the same drug treatments on K562 cells. 
 ABT-737 alone has a modest effect in inducing apoptosis in KCL22 cells, but not in 
K562 cells (Figure 18). The lack of cleaved caspase 3 expression indicated that KCL22 cells 
were more resistant to the cell-killing effects of imatinib alone when compared to K562 cells. 
However, when KCL22 cells were treated with both ABT-737 and imatinib, expression of 
cleaved caspase 3 was greatly enhanced (Figure 18). These results suggest that co-treatment 
with ABT-737 is able to overcome imatinib-resistance associated with the BIM deletion 
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Figure 18: Addition of the BH3-mimetic, ABT-737, sensitizes KCL22 cells to imatinib-  
induced apoptosis. K562 and KCL22 cells were treated with a single agent (imatinib or  
ABT-737) or a combination of both. 48 hours later, whole cell lysates were obtained from  
these cells. Western blot was performed to assess the expression of cleaved caspase 3.  
Western blot image shown is a representative image from three independent experiments. 




 Although I have shown that the KCL22 cell line harboring the BIM deletion 
polymorphism is resistant to imatinib, it is possible that the KCL22 cell line has other 
mutations which could render it resistant to the drug. To provide direct evidence that the BIM 
deletion polymorphism impairs apoptotic signaling, our lab has employed ZFNs to genetically 
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engineer the deletion polymorphism into the genome of an imatinib-sensitive cell line, K562 
(Figure 19).   
 Briefly, we introduced a pair of ZFNs delivered as mRNA transcripts into K562 cells  
 
(Figure 19a). Each ZFN contains a DNA-binding domain, that recognizes a 12-bp sequence  
 
within the 2,903-bp polymorphic sequence, as well as a nuclease domain to create a double- 
 
stranded break. Apart from the ZFNs, we also introduced a repair template containing a 5’ and  
 
3’ homology arm with the 2,903-bp intronic sequence removed (Figure 19a). The double- 
 
stranded break generated by the ZFNs stimulated homologous recombination to take place  
 
with the repair template. Subsequently, we performed single-cell cloning by limiting dilution  
 
and then screened for cells that harbor the BIM deletion polymorphism. Through this process,  
 
we were able to generate clones that were either heterozygous or homozygous carriers of the  
 





































Figure 19: The use of ZFNs to introduce the BIM deletion polymorphism into the  
genome of the K562 CML cell line. (a) K562 cells were nucleofected with a repair template  
containing the BIM intronic deletion together with a pair of ZFNs (mRNA transcripts). The  
introduction of a double-stranded break stimulates homologous recombination with the repair  
template to introduce the deletion into the genome of the K562 cells. (b) Genomic DNA was  
extracted from cells derived from single-cell cloning. PCR was performed using the method  
described in Figure 5c to screen for the deletion. The PCR products amplified were resolved  
in a 1% agarose gel. The KCL22 cell line was used as a positive control for cells that harbor  
the BIM deletion polymorphism. (a and b are adapted from Ng et al., Nature Medicine 18:521- 
528, 2012)140. Note: Genetic modification of the K562 cell line using ZFNs to introduce the  
BIM deletion polymorphism was performed by Dr Ko Tun Kiat from Duke-NUS Graduate  




 Next, I employed real-time RT-PCR to determine whether the introduction of the BIM 
deletion polymorphism was able to alter splicing of BIM. Remarkably, there was a significant 
increase in the expression of exon 3-containing transcripts over transcripts harboring exon 4 
(Figure 20a). Importantly, the increase in exon 3-containing transcripts also occurred in a 
polymorphism-dosage dependent manner as well because the K562 cell line that is 
homozygous for the BIM deletion (BIMintron-/-) has the highest ratio of exon 3- to exon 4-
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containing transcripts (Figure 20a). Using an antibody that is specific for the BIMγ protein, I 
also observed that the increase in exon 3-containing transcripts also correlated with an 
increase in BIMγ protein expression in K562 cells that harbor the BIM deletion polymorphism 
(Figure 20b). 
 To determine whether the induction of exon 4-containing BIM transcripts is impaired 
as a result of the deletion, I have also treated K562 cells with or without the deletion with 
imatinib and then performed real-time RT-PCR analysis to assess the expression of BIM 
transcripts containing exon 4. Remarkably, the amount of exon 4-containing BIM transcripts 
was significantly lower after imatinib treatment in polymorphism-containing cells when 
compared to K562 cells without the deletion (Figure 20c). Collectively, we have direct 
evidence to show that the BIM deletion polymorphism leads to aberrant splicing of the BIM 
gene, resulting in an increased expression of exon 3-containing transcripts over exon 4. 
Furthermore, as a result of the deletion polymorphism, induction of exon 4-containing BIM 




































































Figure 20: K562 subclones harboring the BIM deletion polymorphism showed an  
increase in exon 3-containing BIM transcripts as well as an increase in BIMγ protein  
expression. (a) RNA was isolated from K562 cells with (BIMintron+/-, BIMintron-/-) and without  
the BIM deletion polymorphism (BIMintron+/+). Real-time RT-PCR was performed to determine  
the expression of exon 3- to exon 4-containing BIM transcripts. Experiments were performed  
in triplicates and data is shown as mean ± standard error of the mean. *p < 0.05, **p < 0.01  
compared to K562 cells without the deletion (BIMintron+/+) using Student’s t-test. (b) Western  
blot was performed to determine the expression of BIMγ proteins in K562 cells with or  
without the deletion polymorphism. Western blot image shown is a representative image from  
three independent experiments. (c) K562 cells with or without the deletion polymorphism  
were exposed to 1 μM imatinib. 12 hours later, RNA was extracted from these cells and real- 
time RT-PCR was performed to determine the expression of exon 4-containing transcripts.  
Experiments were performed in triplicates and data is shown as mean ± standard error of the  
mean relative to K562 BIMintron+/+ cells without imatinib treatment. *p < 0.05, **p < 0.01  
compared to K562 BIMintron+/+ cells treated with imatinib using Student’s t-test. (a, b and c are 





 We next sought to investigate whether the polymorphism-containing K562 cells are 
more resistant to imatinib when compared to cells without the polymorphism. To address this 
question, we treated K562 cells with or without the deletion with increasing doses of imatinib. 
Whole cell lysates were obtained from these cells and Western blot was performed to 
determine the protein expression of BIMEL, PARP and cleaved caspase 3. We observed that 
upregulation of BIMEL was diminished in polymorphism-containing K562 cells compared to 
wildtype cells (Figure 21). Importantly, K562 cells homozygous for the deletion expressed 
lower levels of BIMEL after imatinib treatment when compared to cells heterozygous for the 
deletion, suggesting that impaired upregulation of BIMEL occurs in a polymorphism-dosage 
dependent manner. Concomitantly, the impaired apoptotic signaling observed in the 
polymorphism-containing K562 cells was associated with lower levels of apoptotic markers 
such as cleaved PARP and cleaved caspase 3 (Figure 21). To exclude the possibility that 
resistance towards imatinib observed in the polymorphism-containing cells is due to the 
failure of imatinib to suppress BCR-ABL1 downstream signaling, we have also measured the 
expression levels of phosphorylated STAT5A (pSTAT5A)53. Expression of pSTAT5A was 
downregulated upon imatinib treatment in a dose-dependent manner and the extent of 
pSTAT5A downregulation was similar across all cell lines, indicating that signaling 
downstream of BCR-ABL1 has been effectively inhibited (Figure 21). Taken together, these 
results strongly argue for the hypothesis that by promoting the inclusion of BIM exon 3 over 
exon 4, the deletion polymorphism could inhibit the induction of BH3-containing BIM 
















Figure 21: K562 subclones that harbor the BIM deletion polymorphism are less sensitive  
to imatinib-induced apoptosis. K562 cells with (BIMintron+/-, BIMintron-/-) and without the BIM  
deletion polymorphism (BIMintron+/+) were treated with increasing doses of imatinib (0, 0.2,  
0.4, 0.6 μM). 24 hours later, whole cell lysates were obtained from these cells and Western  
blot was performed to determine the expression of pSTAT5A, STAT5A, BIMEL, PARP and  
cleaved caspase 3. Equal loading was determined by probing for the expression of β-actin.  
Western blot image shown is a representative image from three independent experiments.  
(Adapted from Ng et al., Nature Medicine 18:521-528, 2012)140. Note: Imatinib treatment of  
K562 cells with and without the deletion polymorphism and the subsequent Western blot  
were performed by Dr Ko Tun Kiat from Duke-NUS Graduate Medical School, Singapore.  
 
 Next, to determine whether impaired upregulation of BH3-containing BIM isoforms  
 
mediates intrinsic imatinib resistance in our polymorphism-containing K562 cells, I have re- 
 
expressed BIMEL and treated these cells with or without imatinib to assess whether re- 
 
expression of BH3-containing BIM can promote imatinib-induced apoptosis. Western blot  
 
was performed to determine the expression of apoptotic markers, cleaved caspase 3 and  
 
cleaved PARP. Consistent with our earlier observations, less PARP and caspase 3 cleavage  
 
were observed in the polymorphism-containing K562 cells (BIMintron+/-, BIMintron-/-) after  
 
imatinib treatment only, suggesting that polymorphism-containing K562 cells are more  
 
resistant to imatinib than wildtype K562 cells (BIMintron+/+) (Figure 22). Re-expression of  
 
BIMEL alone was able to induce apoptosis modestly across all cell lines. Remarkably, when  
 
combined with imatinib, re-expression of BIMEL was able to enhance apoptotic signaling in  
 
polymorphism-containing K562 cells to almost the same degree as wildtype K562 cells  
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treated with imatinib alone (Figure 22). Taken together, these results strongly argue for the  
 
notion that impaired upregulation of BH3-containing BIM isoforms mediates intrinsic  
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Figure 22: Re-expression of BIMEL promotes imatinib-induced apoptosis in  
polymorphism-containing K562 cells. K562 cells with (BIMintron+/-, BIMintron-/-) and without  
the BIM deletion polymorphism (BIMintron+/+) were nucleofected with either 5 μg of vector  
control plasmids or plasmids expressing FLAG-tagged BIMEL. 24 hours post nucleofection,  
these cells were incubated with DMSO or 0.6 μM imatinib. Whole cell lysates were obtained  
from these cells after another 24 hours and Western blot was performed to determine the  
expression of cleaved caspase 3, PARP,  FLAG-tagged BIMEL and β-actin. Western blot  
image shown is a representative image from three independent experiments. (From Ng et al., 




 Since re-expressing BH3-containing BIM proteins was able to restore the apoptotic  
 
effects of imatinib in our polymorphism-containing K562 cells, we next asked whether the  
 
BH3 mimetic, ABT-737, is able to enhance imatinib-induced apoptosis in these cells as well.  
 
To this end, we treated K562 cells with and without the deletion with a single drug or a  
 
combination of imatinib and ABT-737. Induction of apoptosis was measured by assessing the  
 
expression of apoptotic protein markers by Western blot and also by an ELISA-based DNA  
 
fragmentation assay. Strikingly, we observed a greater expression of cleaved PARP and  
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cleaved caspase 3 in polymorphism-containing K562 cells treated with both drugs when  
 
compared to cells that were treated with imatinib only (Figure 23a). Similarly, the relative  
 
amount of apoptotic cells measured by a DNA fragmentation assay also indicated that  
 
induction of apoptosis was significantly enhanced when polymorphism-containing K562 cells  
 
were treated with both imatinib and ABT-737 when compared to cells that were treated with  
 
imatinib only (Figure 23b). Collectively, these results indicate that imatinib resistance  
 
associated with the BIM deletion polymorphism can be overcome with BH3-mimetics such as  
 
ABT-737. 
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Figure 23: The BH3 mimetic, ABT-737, sensitizes polymorphism-containing K562 cells  
to imatinib-induced apoptosis. (a) K562 cells with (BIMintron+/-, BIMintron-/-) and without the  
BIM deletion polymorphism (BIMintron+/+) were treated with a single drug or a combination of  
imatinib (0.6 μM) and ABT-737 (2.5 μM). Whole cell lysates were obtained 48 hours later 
and Western blot was performed to determine the expression of PARP, cleaved caspase 3 and  
β-actin. (b) K562 cells with and without the deletion polymorphism were treated with drugs in  
the same manner described in (a). 48 hours later, an ELISA-based DNA fragmentation assay  
was performed according to the manufacturer’s protocol to measure the relative amount of  
apoptotic cells. Experiments were performed in triplicates and data is shown as mean ±  
standard error of the mean relative to BIMintron+/+ cells treated with DMSO. (a and b are 
adapted from Ng et al., Nature Medicine 18:521-528, 2012)140. Note: Combination treatment 
of K562 cells with and without the deletion polymorphism, the subsequent Western blot and 
the DNA fragmentation assay were performed by Dr Ko Tun Kiat from Duke-NUS 




Finally, we performed a retrospective analysis to assess whether the BIM deletion 
polymorphism plays a role in mediating responses to TKIs in East Asian individuals with 
CML. We analyzed a total of 203 individuals, with chronic phase CML with and without the 
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polymorphism from Singapore and Malaysia or Japan, by comparing responses with a 
standard dose of imatinib. We classified the clinical responses based on European 
LeukemiaNet criteria104. In both geographic cohorts, individuals with the BIM deletion 
polymorphism have a greater likelihood for developing resistance towards imatinib (Table 3). 
When these subjects were analyzed together, the odds ratio for developing resistance among 
individuals with the BIM deletion polymorphism compared to non-carriers was 2.94 (p=0.02) 
(Table 3). 
 

















Resistant 67 (10) 49 (59) 83 (10) 57 (30) 












Table 3: The BIM deletion polymorphism is associated with clinical resistance to  
imatinib among patients with CML. 203 individuals with chronic phase CML were  
categorized based on their geographic origin and then divided based on whether they harbor  
the BIM deletion polymorphism. The clinical responses for these individuals were then  
classified according to the European LeukemiaNet criteria. Logistic regression analysis was  
carried out to determine the association between the polymorphism and clinical resistance to  
imatinib, while adjusting for any effects of age differences between groups with and without  
the polymorphism. (Adapted from Ng et al., Nature Medicine 18:521-528, 2012)140. Note:  
Statistical analysis was performed by Assistant Professor John C Allen and Dr Ng King  
Pan, both from Duke-NUS Graduate Medical School, Singapore. 
 
3.3 THE BIM DELETION POLYMORPHISM MEDIATES RESISTANCE TO 
TYROSINE KINASE INHIBITORS IN EPIDERMAL GROWTH FACTOR 
RECEPTOR-MUTATED NON-SMALL-CELL LUNG CANCER  
 
 EGFR NSCLC is another kinase-driven malignancy, in which activating mutations in 
EGFR predicts for high response rates among patients treated with EGFR inhibitors such as 
gefitinib22; 23. Furthermore, two independent reports have also shown that upregulation of BIM 
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expression is required for sensitivity towards EGFR inhibitors137; 138. Therefore, we 
hypothesized that the BIM deletion polymorphism may mediate resistance to TKIs in EGFR 
NSCLC. 
 To test this hypothesis, I screened for the BIM deletion polymorphism in a panel of  
 
NSCLC cell lines. Through this screening, I found that the HCC2279 NSCLC cell line,  
 
that harbors activating mutations in EGFR, contains the BIM deletion polymorphism  
 
(Figure 24). Interestingly, HCC2279 is derived from a female Asian patient153; 154.  
 
Furthermore, several groups have demonstrated that HCC2279 is resistant to EGFR  
 
inhibitors155; 156. Our earlier findings suggest that the presence of the BIM deletion  
 






































Figure 24: Identification of the HCC2279 EGFR NSCLC cell line that harbor the BIM  
deletion polymorphism. Genomic DNA was isolated from a panel of NSCLC cell lines. PCR  
was performed using primers that flank the deletion polymorphism. In the absence of the  
deletion, a product of 4,226-bp will be amplified. A shorter product of 1,323-bp is amplified if  
the deletion is present. PCR products were resolved in a 1% agarose gel. PCR amplification of  
the genomic DNA from the KCL22 cell line served as a positive control for the deletion  
polymorphism.  
 
 Since the HCC2279 cell line contains the BIM deletion polymorphism, I predicted  
 
that HCC2279 will be more resistant to the EGFR inhibitor, gefitinib, when compared to other  
 
EGFR NSCLC cell lines that do not harbor the BIM deletion polymorphism.  In addition, I  
 
also predicted that upregulation of exon 4-containing BIM transcripts will be impaired in the  
 
HCC2279 cell line. To test this hypothesis, I treated an EGFR NSCLC cell line that does not  
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harbor the polymorphism (PC9) and the HCC2279 cell line with or without gefitinib. RNA  
 
and whole cell lysates were obtained from these cells 24 hours after treatment. Real-time RT- 
 
PCR showed a modest upregulation of exon 4-containing BIM transcripts in the HCC2279  
 
cell line after gefitinib treatment (< 2-fold upregulation)(Figure 25a). In contrast, there was at  
 
least a 4-fold upregulation of exon 4-containing BIM transcripts when PC9 cells were treated  
 
with gefitinib (Figure 25a). Similarly, expression of BH3-containing proteins (BIMEL, BIML)  
 
after gefitinib treatment was also lower in HCC2279 when compared to PC9 cells (Figure  
 
25b). Consistent with previous reports155; 156, we also observed that HCC2279 cells were  
 
resistant to gefitinib as there was very little expression of cleaved PARP in HCC2279 cells  
 
after gefitinib treatment when compared to PC9 (Figure 25b). Taken together, these results  
 
suggest that the BIM deletion polymorphism could be a predictor for a poorer response to  
 
EGFR inhibitors in EGFR NSCLC, which could be due to impaired upregulation of exon 4- 
 




















































Figure 25: HCC2279 cells are less sensitive to gefitinib compared to PC9 cells, which is  
correlated with a decreased induction of exon 4-containing BIM transcripts and  
proteins. (a) PC9 and HCC2279 cells were treated with or without gefitinib (50 nM). RNA  
was extracted from these cells after 24 hours and real-time RT-PCR was performed to  
determine the expression of exon 4-containing BIM transcripts. Experiments were performed  
in triplicates and data is shown as mean ± standard error of the mean relative to PC9 cells  
without gefitinib treatment. *p < 0.05 compared to PC9 cells treated with gefitinib using  
Student’s t-test. (b) Whole cell lysates were obtained from PC9 and HCC2279 cells treated  
with or without gefitinib (50 nM) for 24 hours. Western blot was performed to assess the  
expression of PARP, BIM and β-actin. Western blot image shown is a representative image  
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Since the reduced sensitivity towards gefitinib was correlated with impaired  
 
upregulation of BH3-containing proteins in HCC2279 cells, I hypothesized that co-treatment  
 
with BH3-mimetics, such as ABT-737, could re-sensitize HCC2279 cells to gefitinib-induced  
 
apoptosis. To test this hypothesis, I treated PC9 and HCC2279 cells with a single drug or a  
 
combination of ABT-737 and gefitinib. Western blot was performed to assess the expression  
 
of apoptotic markers such as cleaved PARP and cleaved caspase 3. Consistent with earlier  
 
results, expression of cleaved PARP and cleaved caspase 3 were modest when HCC2279 cells  
 
were treated with gefitinib only (Figure 26). Expression of phosphorylated EGFR (p-EGFR)  
 
was significantly reduced in HCC2279 cells after gefitinib treatment, suggesting that impaired  
 
induction of apoptosis in HCC2279 cells was unlikely a result of ineffective inhibition of  
 
EGFR signaling (Figure 26). Importantly, induction of apoptosis was enhanced when  
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Figure 26: ABT-737 enhances gefitinib-induced apoptosis in HCC2279 cells. PC9 and  
HCC2279 cells were treated with a single drug or a combination of gefitinib (50 nM) and  
ABT-737 (2.5 μM). 48 hours later, whole cell lysates were isolated from these cells and  
Western blot was performed to determine the expression of PARP, p-EGFR, cleaved caspase  
3 and β-actin. Western blot image shown is a representative image from three independent  
experiments. (From Ng et al., Nature Medicine 18:521-528, 2012)140. 
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 To establish more evidence that the BIM deletion polymorphism renders EGFR 
NSCLC cells less sensitive to EGFR inhibitors, we have also employed ZFNs to genetically 
engineer the BIM deletion polymorphism into the genome of gefitinib-sensitive PC9 cells. 
Using this method, we were able to obtain a PC9 subclone that is homozygous for the deletion 
polymorphism (Figure 27a). In addition, we also observed that the deletion resulted in a 
greater expression of exon 3- to exon 4-containing BIM transcripts when compared to PC9 
cells that do not harbor the deletion (Figure 27b).  
 
 




















Figure 27: De novo generation of the BIM deletion polymorphism into the genome of the  
PC9 EGFR NSCLC cell line. (a) PC9 cells were nucleofected with a repair template  
containing the BIM deletion together with plasmids that express the ZFNs. The  
introduction of a double-stranded break stimulates homologous recombination with the repair  
template to introduce the deletion into the genome of the PC9 cells. Genomic DNA was  
extracted from cells derived from single-cell cloning. PCR was performed using the method  
described in Figure 5b to screen for the deletion. The PCR products amplified were resolved  
in a 1% agarose gel. The HCC2279 cell line was used as a positive control for cells that  
harbor the BIM deletion polymorphism. (b) RNA was extracted from PC9 cells with  
(BIMintron-/-) and without (BIMintron+/+) the BIM deletion polymorphism. Real-time RT-PCR was  
performed to determine the expression of endogenous BIM transcripts containing exon 3 over  
exon 4. Experiments were performed in triplicates and data is shown as mean ± standard error  
of the mean. *p < 0.05 compared to PC9 cells without the BIM polymorphism using Student’s  
t-test. (a and b are from Ng et al., Nature Medicine 18:521-528, 2012)140. Note: The 
generation of genome-edited PC9 cells was performed by Dr Ko Tun Kiat from Duke-NUS 




 Next, we determined whether the polymorphism-containing PC9 cells were less 
sensitive to gefitinib when compared to PC9 cells without the deletion polymorphism. To 
achieve this objective, we treated the genome-edited PC9 cells with increasing doses of 
gefitinib and then performed Western blot to assess the expression of apoptotic markers, 
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cleaved PARP and cleaved caspase 3. Expression of p-EGFR was downregulated in a dose-
dependent manner to a similar extent in PC9 cells with (BIMintron-/-) and without (BIMintron+/+) 
the BIM deletion polymorphism (Figure 28a). Consistent with the observations made in 
HCC2279 cells, PC9 cells with the deletion (BIMintron-/-) expressed lower levels of cleaved 
PARP and cleaved caspase 3 after gefitinib treatment when compared to PC9 cells without the 
deletion (BIMintron+/+) (Figure 28a). The impaired induction of apoptosis in BIMintron-/-  PC9 
cells was also associated with impaired upregulation of BIMEL (Figure 28a). We then 
performed an ELISA-based DNA fragmentation assay as an alternative approach to measure 
the relative amount of cells that underwent apoptosis after treatment with gefitinib. Consistent 
with the Western blot analysis, we observed that the induction of apoptosis was impaired in 
PC9 cells harboring the deletion polymorphism when compared to cells without the deletion 
(Figure 28b). Taken together, these results strongly argue for the hypothesis that the BIM 
deletion polymorphism mediates resistance towards EGFR inhibitors in EGFR NSCLC as a 
result of diminished upregulation of BH3-containing BIM proteins.  
 




































Figures 28: PC9 subclones that harbor the BIM deletion polymorphism are less sensitive  
to gefitinib-induced apoptosis. (a) PC9 cells with (BIMintron-/-) and without (BIMintron+/+) the  
BIM deletion polymorphism were treated with increasing doses of gefitinib (0, 10, 25, 50  
nM). Whole cell lysates were extracted from these cells 48 hours later and Western blot was  
performed to determine the expression of p-EGFR, BIM, PARP, cleaved caspase 3 and β- 
actin. Western blot image shown is a representative image from three independent  
experiments. (b) PC9 cells with (BIMintron-/-) and without (BIMintron+/+) the BIM deletion  
polymorphism were treated with increasing doses of gefitinib (0, 10, 25, 50 nM). 48 hours  
later, an ELISA-based DNA fragmentation assay was performed according to the  
manufacturer’s protocol to determine the relative induction of apoptosis. Experiments were  
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performed in triplicates and data is shown is as mean ± standard error of the mean relative to  
relative to BIMintron+/+ PC9 cells treated with DMSO. *p < 0.05 compared to BIMintron+/+ PC9  
cells treated with 50 nM gefitinib using Student’s t-test. (a and b are adapted from Ng et al.,  
Nature Medicine 18:521-528, 2012)140. Note: Both the Western blot and the DNA  





 We next sought to investigate whether co-treatment with the BH3-mimetic, ABT-737,  
 
could restore sensitivity towards gefitinib in PC9 cells harboring the deletion polymorphism.  
 
Our approach to this experiment is to treat PC9 cells with (BIMintron-/-) and without  
 
(BIMintron+/+) the BIM deletion polymorphism with a single drug or a combination of gefitinib  
 
and ABT-737. Western blot was performed to determine the expression of cleaved PARP and  
 
cleaved caspase 3. We observed a greater expression of cleaved PARP and cleaved caspase 3  
 
when polymorphism-containing PC9 cells (BIMintron-/-) were treated with both gefitinib and  
 
ABT-737 when compared to cells that were treated with gefitinib only (Figures 29a). In a  
 
parallel experiment, we have also performed an ELISA-based DNA fragmentation assay and  
 
we also observed a greater induction of apoptotic cell death when BIMintron-/- PC9 cells were  
 
treated with both gefitinib and ABT-737 (Figure 29b). Collectively, these results indicate that  
 
BH3 mimetics can be employed to overcome gefitinib resistance associated with the BIM  
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Figure 29: Addition of ABT-737 overcomes intrinsic resistance to gefitinib in 
polymorphism-containing PC9 cells. (a) PC9 cells with (BIMintron-/-) and without  
(BIMintron+/+) the BIM deletion polymorphism were treated with a single drug or a combination  
of gefitinib (50 nM) and ABT-737 (2.5 μM). Whole cell lysates were obtained from these  
cells after 48 hours and Western blot was performed to determine the expression levels of  
PARP, cleaved caspase 3 and β-actin. Western blot image shown is a representative image  
from three independent experiments. (b) PC9 cells with (BIMintron-/-) and without (BIMintron+/+)  
the BIM deletion polymorphism were treated with a single drug or a combination of gefitinib  
and ABT-737. An ELISA-based DNA fragmentation assay was performed 48 hours later.  
Experiments were performed in triplicates and data is shown as mean ± standard error of the  
mean relative to BIMintron+/+ PC9 cells treated with DMSO. (a and b are adapted from Ng et al.,  
Nature Medicine 18:521-528, 2012)140. Note: Both the Western blot and the DNA  





 Since introducing the BIM deletion polymorphism into the genome renders EGFR 
NSCLC cells more resistant to EGFR inhibitors in vitro, we next asked whether the BIM 
deletion polymorphism is associated with a shorter PFS among individuals with EGFR 
NSCLC that were treated with EGFR inhibitors. We analyzed a total of 141 individuals with 
EGFR NSCLC from Singapore and Japan that were treated with EGFR inhibitors. These 
patients were divided into two groups based on whether they harbor the BIM deletion 
polymorphism. PFS was estimated for each group using the Kaplan-Meier method. We found 
that the BIM deletion polymorphism was predictive of a significantly shorter PFS (Figure 30). 
A median PFS of 6.6 months was observed in subjects with the deletion polymorphism, 
whereas individuals without the polymorphism had a PFS of 11.9 months (p=0.0027) (Figure 
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30). Importantly, subjects with or without the deletion polymorphism were not associated with 





Figure 30: The BIM deletion polymorphism predicts for a shorter progression free  
survival among NSCLC patients with activating mutations in EGFR. 141 individuals with  
EGFR NSCLC from Singapore and Japan were divided into two groups based on whether  
they harbor the BIM deletion polymorphism. A Kaplan-Meier analysis was performed to  
determine the PFS for each group. (From Ng et al., Nature Medicine 18:521-528, 2012)140.  
Note: Kaplan-Meier analysis was performed by Assistant Professor John C Allen, Dr Ng  






 In this chapter, I have shown that the BIM deletion polymorphism mediates resistance 
to TKIs in CML and EGFR NSCLC. Mechanistically, TKI-resistance mediated by the 
deletion is due to the impaired induction of BH3 (exon 4)-containing BIM isoforms as a result 
of aberrant pre-mRNA splicing. I have also demonstrated that TKI-resistance associated with 
the BIM deletion polymorphism can be overcome by using the BH3-mimetic, ABT-737. 
Finally, we have also established that the BIM deletion polymorphism can serve as a 









Identification of cis-acting RNA elements and trans-acting 














 Alternative splicing is an important process in which pre-mRNAs are spliced 
differentially, leading to an increase to the diversity of the proteome157. As a result, the protein 
isoforms generated by alternative splicing can have considerable functional differences. A 
notable example of this is the generation of different isoforms of BIM described earlier, 
whereby the BIMγ isoform is not apoptotic, whereas the BIMEL, BIML and BIMS isoforms are 
pro-apoptotic. The functional differences between these isoforms arise due to the mutually 
exclusive inclusion of either exon 3 or exon 4. As a result, the exon 3-containing BIMγ 
isoform is not apoptotic because it lacks the BH3 domain encoded in exon 4 which is required 
for the induction of apoptosis.  
 In general, alternative splicing is regulated by cis-acting RNA elements and trans-
acting factors143. The essential cis-acting RNA elements that are required for pre-mRNA 
splicing are the 5’ splice site, the 3’ splice site, as well as the branchpoint sequence which 
includes an adenine residue that functions as a nucleophile for the catalysis of the first step of 
splicing (Figure 31)143; 158. The 5’ splice site has a consensus sequence of CAG/GURAGU 
(where “/” represents the exon/intron junction and “R” represents purine nucleotides) whereas 
the consensus sequence for the 3’ splice site is YYYYYYYYYNCAG/GU (where “/” 
represents the intron/exon junction, “Y” represents pyrimidine nucleotides and “N” represents 
any nucleotide) (Figure 31)158; 159; 160. Although the splice sites and the branchpoint sequence 
are essential, other RNA elements are required to regulate alternative splicing. Depending on 
the location of these RNA elements, sequences that promote alternative splicing are known as 
exonic (ESE) or intronic splicing enhancers (ISE). In contrast, sequences that repress 
inclusion of an exon are known as exonic (ESS) or intronic splicing silencers (ISS) (Figure 
31)147.  
Trans-acting factors regulate pre-mRNA splicing by associating with cis-acting RNA 
elements161. During the early stage of spliceosome assembly, the 5’ splice site and the 
branchpoint sequence are bound by small nuclear RNAs assembled as the U1 and the U2 
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small nuclear ribonucleoprotein particles (snRNPs), respectively. The 3’ splice site is bound 
by the protein heterodimer, U2 auxiliary factor (U2AF). U2AF65 binds to the polypyrimidine 
tract whereas U2AF35 binds to the AG dinucleotide at the intron/exon junction (Figure 31)143.  
 Additional splicing factors are required for the proper assembly of the spliceosome.  
 
For example, serine/arginine-rich (SR) proteins are usually involved in promoting inclusion of  
 
an exon by interacting with ESE or ISE162. While in contrast, repression of exon inclusion is  
 
usually regulated by heterogeneous nuclear ribonucleoproteins (hnRNPs) which associate  
 



















Figure 31: Cis-acting RNA elements and trans-acting factors that regulate pre-mRNA 
splicing. The exons are represented by the yellow boxes and the intron is represented by a  




hnRNPs are a large protein family. In this family, the hnRNP H protein has been 
extensively studied. hnRNP H consists of three RNA recognition motifs163 and it is also rich 
in glycine residues at its carboxy terminus which are predicted to facilitate interactions with 
other hnRNP H proteins164. Like most hnRNPs, hnRNP H can repress exon inclusion when it 
associates with ESS in fibroblast growth factor receptor 2163, α-tropomyosin165 and β-
tropomyosin166 transcripts. However, depending on the context of the binding site, hnRNP H 
has also been shown to activate exon inclusion by associating with elements found 
downstream of the 5’ splice site in c-src164, BCL-X167 and GRIN1168 transcripts. 
Polypyrimidine tract binding protein 1 (PTBP1), also known as hnRNP I, is a closely related 
protein that has also been studied as a splicing repressor. Unlike hnRNP H, PTBP1 consists of 
four RNA recognition motifs which have a preference to associate with pyrimidine-rich 
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sequence containing cytosines169. A simple model for splicing repression mediated by PTBP1 
involves sterically impeding spliceosomal proteins from being recruited at the splice sites169.  
Alternative splicing of BIM can give rise to numerous protein isoforms148. However,  
there is no known cis-acting RNA element that has been reported which can regulate splicing 
of BIM. In the previous chapter, I have shown that a deletion polymorphism in the second 
intron of the BIM gene enhances inclusion of exon 3 over exon 4. These results suggest that 
the deleted region contains regulatory elements that promote skipping of exon 3. Therefore, 
cells that harbor the deletion favor the inclusion of exon 3 over exon 4. In this chapter, I aim 
to identify cis-acting RNA element(s) within the deleted fragment that enhances skipping of 
BIM exon 3. To address this question, I have performed a systematic mutation analysis by 
introducing deletions, substitutions and point mutations to define elements that can repress 
exon 3 inclusion. In addition, I will also be identifying trans-acting factors that regulate 
splicing of BIM exon 3. To answer this question, I used siRNAs to knockdown predicted 
proteins that could regulate splicing of endogenous BIM exon 3. In addition, I have co-
nucleofected cells with siRNAs and BIM minigene constructs as well to assess whether the 
predicted proteins regulate exon 3 splicing via the 2,903-nucleotide (nt) deleted fragment.  
 
4.2 DELETION AND SUBSTITUTION ANALYSIS TO IDENTIFY CIS-ELEMENTS 
THAT REGULATE SPLICING OF BIM EXON 3 
 
The pI-12 minigene system has been shown to recapitulate the splicing pattern of  
endogenous fibroblast growth factor receptor 2 and lysyl hydroxylase 2144; 170. In addition, I 
have also demonstrated that the WT and the DEL minigenes recapitulated the endogenous 
splicing pattern of the BIM gene, with and without the BIM deletion polymorphism, in 
primary CML samples (Figures 7 and 8). Therefore, the WT minigene, that was derived from 
the pI-12 minigene, could be used to determine cis-regulatory elements within the 2,903-nt 
deleted fragment that repress inclusion of exon 3. To define elements within the 2,903-nt 
deleted fragment that can repress inclusion of exon 3, I have generated a series of forward 
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sequential deletions in the context of the WT minigene (Figure 32a). K562 cells were 
nucleofected with these minigenes and the ratio of U-E3 to U-E4 transcripts was determined. 
Interestingly, deletions removing most of the 2,903-nt, as demonstrated by the Δ1 to Δ9 
deletions, failed to cause an appreciable increase in exon 3 inclusion (Figure 32b). Strikingly, 
inclusion of exon 3 over exon 4 remain low even in Δ10, which consist only the last 322-nt at 
the 3’end of the deletion. A significant increase in exon 3 inclusion over exon 4 was only 
observed when the last 322-nt were removed as shown in Δ11 (Figure 32b). Taken together, 
these results indicate that the last 322-nt from +2,582 to +2,903 of the deletion are sufficient 
for repressing the inclusion of exon 3.  
 Reverse deletions, starting from the 3’end of the deletion polymorphism, were also 
generated (Figure 32c). Intriguingly, removing the last 322-nt only while keeping the 
remaining sequence intact in REV1 resulted in a modest increase in exon 3 inclusion (Figure 
32d). Removing an additional 680-nt in REV2 did not lead to a significant change in exon 3 
inclusion over exon 4. However, a greater increase in exon 3 inclusion was observed when 
further reverse deletions (REV3, REV4, DEL) were made (Figure 32d). Collectively, these 
data suggest that the 2,903-nt deleted fragment contains multiple redundant elements that 
promote skipping of exon 3. Furthermore, the results also indicate that the last 322-nt 
comprising +2,582 to +2,903 of the deletion are sufficient but not necessary for exon 3 
exclusion. Nonetheless, it is still important to study cis-regulatory elements within the 2,903-
nt deleted fragment since this will provide insights on how BIM is regulated by pre-mRNA 
splicing.  
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Figure 32: Forward and reverse deletion analysis revealed that +2,582 to +2,903 of the  
BIM intronic deletion is sufficient but not necessary for excluding BIM exon 3. (a)  
Schematics of the forward deletions in the context of the WT minigene. The red line indicates  
the deleted fragment. Intronic sequences upstream and downstream of the deletion are  
indicated by the green and blue line, respectively. (b) Real-time RT-PCR of RNA isolated  
from nucleofected K562 cells with the indicated forward deletion constructs to assess the  
expression of minigene products containing either exon 3 or exon 4. Experiments were  
performed in triplicates and the relative E3: E4 ratio was determined by normalizing the E3:  
E4 ratio of all minigenes to the E3: E4 ratio of the WT minigene. Error bars represent ±  
standard error of the mean. (c) Schematics of the reverse deletions in the context of the WT  
minigene. (d) Real-time RT-PCR of RNA isolated from K562 cells 24 hours post- 
nucleofection with the indicated reverse deletion constructs to assess the expression of  
minigene products containing either exon 3 or exon 4. Experiments were performed in  
triplicates and the relative E3: E4 ratio was determined by normalizing the E3: E4 ratio of all  
minigenes to the E3: E4 ratio of the WT minigene. Error bars represent ± standard error of the  
mean. 
 
   
 
 The significant increase in exon 3 inclusion observed when the last 322-nt were 
 
removed in the forward deletion constructs could be a result of excessive shortening of  
 
the intron, but not due to the removal of cis-regulatory elements that repress inclusion of exon  
 
3. To address this possibility, I have created a size-matched control of Δ10 by substituting  
 
+2,582 to +2,903 of the deletion with an inversion of this sequence (Figure 33a). Replacing  
 
+2,582 to +2,903 of the deletion with this inversion (Δ10inv) led to an increase in exon 3  
 
inclusion when compared to Δ10 (Figure 33b). These results demonstrate that the significant  
 
increase in exon 3 inclusion due to the removal of +2,582 to +2,903 of the deletion is a result  
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Figure 33: Substitution analysis confirmed that +2,582 to +2,903 of the deletion contain  
cis-elements that exclude BIM exon 3. (a) Schematic diagram of the Δ10inv minigene that  
harbors an inversion of +2,582 to +2,903 of the deletion. (b) Real-time RT-PCR of RNA  
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extracted from K562 cells that were nucleofected with the Δ10, Δ10inv or Δ11 minigene to  
assess the expression of minigene products containing either exon 3 or exon 4. Experiments  
were performed in triplicates and the relative E3: E4 ratio was determined by normalizing the  
E3: E4 ratio of all minigenes to the E3: E4 ratio of the Δ10 minigene. Error bars represent ±  




I next embarked to further delineate critical elements within +2,582 to +2,903 of the 
deletion that is important for exon 3 exclusion. To this end, I deleted internal sequences of 
approximately 64-nt in the context of the Δ10 minigene (Figure 34a) and then tested the 
effects of these deletions on exon 3 splicing. Interestingly, most of these internal deletions 
resulted in a modest increase in exon 3 inclusion when compared with Δ11 which lacked any 
sequence from the deletion polymorphism (Figure 34b). Furthermore, an internal deletion 
from +2,774 to +2,837 (MUT4) did not lead to an increase in exon 3 inclusion, indicating that 
this sequence does not harbor any elements that is required for repressing splicing of exon 3. 
Taken together, these results suggest that there are multiple elements within +2,582 to +2,903 




          






































Figure 34: Identification of cis-elements regulating splicing of exon 3 within +2,582 to  
+2,903 of the BIM deletion polymorphism. (a) Outline of the internal deletions in the  
context of the Δ10 minigene. Sequences that are deleted are denoted by the dotted red lines,  
whereas sequences that are retained are denoted by the solid red lines. The numbers that are  
indicated above each dotted red line represent the position of the sequence that are removed.  
(b) K562 cells were nucleofected with 1 μg of each minigene. 24 hours later, RNA from  
these cells was isolated and real-time RT-PCR was performed to assess the ratio of minigene  
products containing either exon 3 or exon 4. Experiments were performed in triplicates and  
the relative E3: E4 ratio was determined by normalizing the E3: E4 ratio of all minigenes to  




Because the internal deletions described above failed to result in a striking change in 
exon 3 inclusion, I generated a series of minigenes harboring larger deletions of at least 160-nt 
in the context of the Δ10 minigene (Figure 35a). Consistent with the previous result, removing 
half of the sequence on either end of the remaining 322-nt (Δ10A and Δ10B) resulted in an 
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increase in exon 3 inclusion, suggesting that multiple elements that repress splicing of exon 3 
are found within +2,582 to +2,903 of the deletion (Figure 35b). Remarkably, removing the 
first and the last 81-nt from the remaining 322-nt (Δ10C), while retaining +2,663 and +2,822 
of the deletion, resulted in a greater increase in exon 3 inclusion when compared to Δ10 
(Figure 35b). However, the increase in exon 3 inclusion over exon 4 could not reach the levels 
obtained when the entire 322-nt were removed (Δ11). These results suggest that most, but not 
all, of the elements that are necessary for repressing splicing of exon 3 are found in +2,582 to 
+2,662 and +2,823 to +2,903 of the deletion. The increase in exon 3 inclusion was also lower 
when +2,582 to +2,662 and +2,823 to +2,903 of the deletion were retained in the minigene 
(Δ10D) when compared to the Δ10A and the Δ10B minigene (Figure 35b). This observation 
indicates that +2,582 to +2,662 and +2,823 to +2,903 of the deletion contain most of the 
regulatory elements that are sufficient for repressing splicing of exon 3. Consistent with this 
observation, a modest increase in exon 3 inclusion was observed when either +2,582 to 
+2,662 or +2,823 to +2,903 of the deletion (Δ10E and Δ10F) was retained in the minigene 
(Figure 35b). Taken together, these results suggest that +2,582 to +2,662 and +2,823 to 
+2,903 of the deletion contain most, but not all, of the elements at the 3’end of the 2,903-nt 
fragment that repress exon 3 inclusion.  
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Figure 35: +2,582 to +2,662 and +2,823 to +2,903 of the deletion contain most of the cis- 
elements at the 3’end of the 2,903-nt fragment that repress exon 3 inclusion. (a)  
Schematic of the deletions in the context of the Δ10 minigene. Sequences that are deleted are  
indicated by the dotted red lines. Sequences that are retained are denoted by the solid red  
lines. The numbers above the solid red lines indicate the position of the sequence that are  
retained. (b) K562 cells were nucleofected with 1 μg of each minigene. 24 hours later, RNA  
from these cells was isolated and real-time RT-PCR was performed to assess the ratio of  
minigene products containing either exon 3 or exon 4. Experiments were performed in  
triplicates and the relative E3: E4 ratio was determined by normalizing the E3: E4 ratio of all  






4.3 A 23-NT INTRONIC SPLICING SILENCER IS LOCATED AT THE 3’END OF 
THE BIM DELETION POLYMORPHISM 
 
To further define elements within +2,582 to +2,662 and +2,823 to +2,903 of the 
deletion polymorphism that is important for repressing splicing of exon 3, I employed a 
computational approach to predict for putative splicing silencer elements. Five programs were 
used for prediction: (1) SFmap171, (2) PESX172, (3) Splicing Rainbow173, (4) Human Splicing 
Finder174 and (5) SpliceAid175. Because these programs often give wrong predictions, putative 
silencer elements are selected for functional studies only if they are predicted by at least two 
programs.   
Three putative PTBP1 binding sites were predicted within +2,582 to +2,662 of the 
deletion polymorphism (Figure 36a). Because PTBP1 is known to inhibit the splicing of exons 
in numerous transcripts176; 177; 178, deletions in the context of the Δ10E minigene were 
generated to assess the role of these putative PTBP1 binding sites on the splicing of exon 3 
(Figure 36a).  
Removing only one of the predicted PTBP1 binding sites in the Δ10E1 and the Δ10E2 
minigenes did not result in a significant increase in exon 3 inclusion when compared with the 
Δ10E minigene (Figure 36b). Interestingly, removing the third predicted PTBP1 binding site 
in the Δ10E3 minigene led to a slight decrease in exon 3 inclusion when compared with Δ10E 
(Figure 36b). Due to the fact that each of the predicted PTBP1 binding sites may be sufficient 
but not necessary for repressing splicing of exon 3, the Δ10E4 minigene was generated which 
has all three predicted PTBP1 binding sites removed (Figure 36a). However, the removal of 
all three predicted PTBP1 binding sites only led to a modest increase in exon 3 inclusion 
when compared with the Δ10E minigene (Figure 36b). Taken together, these results suggest 
that the three predicted PTBP1 binding sites within +2,582 to +2,662 of the deleted fragment 
do not play a major role in repressing splicing of exon 3.  
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Figure 36: Further mapping of cis-regulatory elements within +2,582 to +2,662 of the  
BIM deletion polymorphism. (a) Schematics of the deletions made on the Δ10E minigene to  
remove the putative PTBP1 binding sites. The predicted PTBP1 binding sites on Δ10E are  
underlined and typed in red. Deletions made are indicated by dashes. (b) K562 cells were  
nucleofected with 1 μg of each minigene. 24 hours later, RNA was extracted from these cells  
and real-time RT-PCR was performed to assess the ratio of minigene products containing  
either exon 3 or exon 4. Δ11 serves as a positive control for enhanced exon 3 splicing due to  
the lack of sequence from the BIM deletion polymorphism that could repress splicing of exon  
3. Experiments were performed in triplicates and the relative E3: E4 ratio was determined by  
normalizing the E3: E4 ratio of all minigenes to the E3: E4 ratio of the Δ10 minigene. Error  








In silico prediction indicated the presence of three putative silencer elements within  
 
+2,823 to +2,903 of the deletion polymorphism (Figure 37a). To address whether these  
 
predicted silencer elements play a role in repressing splicing of exon 3, additional deletions  
 
were made in the context of the Δ10F minigene. Remarkably, removing a 23-nt sequence  
 
closest to the 3’end of the deletion (Δ10F3) resulted in a dramatic increase in exon 3 inclusion  
 
when compared with Δ10F (Figure 37b). Importantly, the extent of exon 3 inclusion was  
 
comparable to Δ11, which does not contain any sequence from the BIM deletion  
 
polymorphism that could repress splicing of exon 3. This observation indicates that the 23-nt  
 
sequence removed in Δ10F3 contains most of the silencing activity within +2,823 to +2,903  
 
of the deletion polymorphism that repress exon 3 splicing. In contrast, little silencer activity  
 
was detected when the other two predicted silencer elements (Δ10F1 and Δ10F2) were  
 
removed (Figure 37b). Collectively, these results suggest that a 23-nt ISS could be located at  
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Figure 37: Identification of a 23-nt ISS that is important for excluding BIM exon 3. (a)  
Schematics of the deletions made on the Δ10F minigene to remove the predicted splicing  
silencer elements. The predicted splicing silencer elements on Δ10F are underlined and typed  
in red. Deletions to the sequence are indicated by dashes. (b) K562 cells were nucleofected  
with 1 μg of each minigene. 24 hours post nucleofection, the cells were harvested for RNA  
extraction. Real-time RT-PCR was performed to determine the ratio of minigene products  
containing either exon 3 or exon 4. Δ11 serves as a positive control for enhanced exon 3  
splicing. Experiments were performed in triplicates and the relative E3: E4 ratio was  
determined by normalizing the E3: E4 ratio of all minigenes to the E3: E4 ratio of the Δ10  




 To exclude the possibility that the increase in exon 3 inclusion that was observed after 
removing the putative 23-nt ISS was due to excessive shortening of the intron, a size-matched 
control of the Δ10F minigene was created (Δ10F3inv).  The Δ10F3inv minigene harbors an 
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inversion of the putative 23-nt ISS (Figure 38a). KCL22 cells were also nucleofected with 
these minigenes to exclude the possibility that the increase in exon 3 inclusion observed when 
the putative 23-nt ISS was removed, was a cell-specific effect restricted to K562 cells only. 
Remarkably, an inversion of the 23-nt ISS led to an increase in exon 3 inclusion when 
compared to Δ10F in K562 and also in KCL22 cells (Figure 38b). Importantly, the increase in 
exon 3 inclusion in Δ10F3inv was comparable to Δ10F3, which has the putative ISS deleted 
(Figure 38b). Taken together, these results strongly argue for the hypothesis that the 23-nt ISS 
identified earlier contain regulatory elements that repress splicing of exon 3. Furthermore, the 























































Figure 38: Substitution analysis confirmed that the putative 23-nt ISS harbors cis- 
regulatory elements that repress splicing of exon 3. (a) Schematic diagram of the Δ10F3inv  
minigene that contains an inversion of the putative 23-nt ISS. The putative 23-nt ISS in Δ10F  
and the inversion mutation in Δ10F3inv are underlined and typed in red. The deleted sequence  
in Δ10F3 is indicated by dashes. (b) K562 and KCL22 cells were nucleofected with 1 μg of  
Δ10,Δ10F, Δ10F3, Δ10F3inv and Δ11 minigenes . Total RNA was prepared after 24 hours  
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and analyzed by real-time RT-PCR to determine the ratio of minigene products that contain  
either exon 3 or exon 4.  The Δ11 minigene served as a positive control for enhanced exon 3  
inclusion. Experiments were performed in triplicates and the relative E3: E4 ratio was  
determined by normalizing the E3: E4 ratio of all minigenes to the E3: E4 ratio of the Δ10  




4.4 CONCLUSION (PART 1) 
 
 Although we have shown that intrinsic resistance to TKIs mediated by the BIM  
 
deletion polymorphism is a result of aberrant splicing of the BIM gene, the precise mechanism  
 
of exon 3 silencing mediated by the polymorphic fragment is still not understood. Using  
 
deletion and substitution analysis, I have shown that with the exception of +1,901 to +2,581 of  
 
the deletion, the 2,903-nt deleted fragment contains numerous redundant elements that repress  
 
splicing of exon 3 (Figure 39). Furthermore, I have also demonstrated that a 322-nt sequence  
 
at the 3’end of the deletion (+2,582 to +2,903) contains regulatory elements that are sufficient  
 
but not necessary for repressing exon 3 splicing. Within this 322-nt sequence, I have also  
 
identified a 23-nt ISS that is important for the exclusion of exon 3 (Figure 39). Further  
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Figure 39: Cis-regulatory elements repressing exon 3 inclusion via the BIM deletion  
polymorphism. The two asterisks represent sequences that contain most of the silencing  
activity within +2,582 to +2,903 of the deleted fragment. The diagram is not drawn to scale.  
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4.5 THE ROLE OF PTBP1 IN REPRESSING THE INCLUSION OF BIM EXON 3  
 
I have shown earlier that three putative PTBP1 binding sites were predicted within 
+2,582 to +2,662 of the BIM deletion polymorphism (Figure 36). However, removing these 
putative PTBP1 binding sites failed to cause a significant increase in exon 3 inclusion (Figure 
36). This observation suggests that PTBP1 may not be critical for the splicing of exon 3. 
However, data from a recent paper that screened for RNA sequences that interact with PTBP1 
in HeLa cells indicated that PTBP1 could associate with the deleted fragment at position 
+1,084 to +1,100179. Therefore, it is possible that PTBP1 could regulate splicing of exon 3 by 
interacting with other sequences within the 2,903-nt deleted fragment.  
 To address whether PTBP1 plays a role in the regulation of exon 3 splicing, I used  
 
siRNAs to silence PTBP1 expression and assessed the ratio of exon 3- to exon 4-containing  
 
endogenous BIM transcripts. Three different siRNA duplexes against PTBP1 were used in this  
 
experiment to control for off-target effects. Western blotting showed that PTBP1 protein  
 
levels were greatly reduced upon siRNA knockdown (Figure 40a).  When PTBP1 expression  
 
was silenced, analysis of the endogenous BIM transcripts revealed that there was nearly a 2- 
 
fold increase in the ratio of exon 3- to exon 4-containing transcripts (Figure 40b).  
 









































Figure 40: Silencing of PTBP1 enhanced the inclusion of endogenous BIM exon 3. (a)  
Western blot analysis for PTBP1 protein levels after nucleofecting K562 cells with control or  
three different PTBP1-specific siRNA duplexes. “U” represents control cells that were not  
subjected to nucleofection. Equal loading in each lane was determined by assessing the  
expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). (b) K562 cells were  
nucleofected with 100 nM of either control or PTBP1-specific siRNA duplexes. RNA was  
isolated from these cells 48 hours later and analyzed by real-time RT-PCR for the ratio of  
endogenous BIM transcripts containing either exon 3 or exon 4. Experiments were performed  
in triplicates and the relative E3: E4 ratio was determined by normalizing to the E3: E4 ratio  
of K562 cells that were not subjected to nucleofection.**p < 0.01 when compared to K562  




Because PTBP1 could regulate splicing of exon 3 independent of the BIM deletion  
 
polymorphism, I next assessed whether the 2,903-bp intronic sequence is required for exon 3  
 
exclusion. To answer this question, I nucleofected K562 cells with control or PTBP1-specific  
 
siRNA duplexes as well as the WT, Δ10, Δ10E or Δ11 minigenes (Figure 41a). Minigene  
 
products harboring either exon 3 or exon 4 were analyzed by real-time RT-PCR. Silencing of  
 
PTBP1 using two different siRNA duplexes failed to cause a significant increase in exon 3  
 
inclusion when cells were nucleofected with the Δ10E minigene (Figure 41b). This finding is  
 
consistent with earlier observations that removal of the three putative PTBP1 binding sites in  
 
Δ10E also failed to cause a significant increase in exon 3 inclusion (Figure 36). A significant  
 
increase in exon 3 inclusion was also not observed in Δ10 after PTBP1 was depleted (Figure  
 
41b). This suggest that PTBP1 does not regulate exclusion of exon 3 via +2,582 to +2,903 of  
 
the BIM deletion polymorphism. Surprisingly, knockdown of PTBP1 also did not result in a  
 88 
 
significant increase in exon 3 inclusion when cells were nucleofected with the WT minigene  
 
that has the entire 2,903-nt deleted fragment intact (Figure 41b). Taken together, these results  
 
suggest that PTBP1 does not regulate exclusion of exon 3 via the 2,903-nt deleted fragment.  
 
Because these minigenes do not contain all the cis-elements in introns 2 and 3, our results  
 
suggest that PTBP1 regulates splicing of exon 3 via other cis-elements within BIM,  
 
at least in K562 cells.  
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Figure 41: Silencing of PTBP1 does not cause a significant increase in minigene products  
that contain exon 3. (a) Schematics of the WT, Δ10, Δ10E and Δ11 minigenes. Sequences  
that are deleted are indicated by the dotted red lines. Sequences that are retained are denoted  
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by the solid red lines. The numbers above the solid red lines indicate the position of the  
sequence that are retained. (b) K562 cells were either nucleofected with 100 nM of non- 
specific or PTBP1-specific siRNA duplexes. 24 hours later, these cells were nucleofected with  
the minigenes described in (a). RNA from these cells was extracted after another 24 hours  
and real-time RT-PCR was performed to assess the expression of minigene products that  
contain either exon 3 or exon 4. Experiments were performed in triplicates and  
the relative E3: E4 ratio was determined by normalizing to the E3: E4 ratio of K562 cells that  
were not nucleofected with siRNA. Error bars represent ± standard error of the mean. 
 
Since siRNA-mediated knockdown of PTBP1 enhanced the inclusion of BIM exon 3,  
 
we hypothesized that downregulation of PTBP1 suppresses induction of BH3-containing  
 
BIM proteins, such as BIMEL, BIML and BIMS, and impairs induction of imatinib-induced  
 
apoptosis. Consistent with our hypothesis, knockdown of PTBP1 suppressed imatinib- 
 
induced apoptosis in K562 cells, as indicated by the reduced expression of cleaved PARP and  
 
cleaved caspase 3 (Figure 42). Furthermore, downregulation of PTBP1 also impaired the  
 
upregulation of BIML and BIMS, which are more potent inducers of apoptosis than  
 
BIMEL141. Intriguingly, impaired induction of BIMEL was not observed consistently when we  
 
used two different siRNA duplexes to knockdown PTBP1 (Figure 42). One possible  
 
explanation could be that unlike BIML and BIMS, BIMEL can be degraded by the  
 
proteasome pathway as a result of phosphorylation by ERK1/2 139; 180; 181. As a result, even  
 
when the inclusion of exon 4-containing BIM transcripts is suppressed by the downregulation  
 
of PTBP1, the inhibition of ERK1/2 signaling by imatinib can still increase BIMEL protein  
 


















Figure 42: Downregulation of PTBP1 inhibits imatinib-induced apoptosis. K562 cells 
were nucleofected with either control or PTBP1-specific siRNA duplexes. 24 hours later, 
these cells were treated with increasing doses of imatinib (0, 0.25, 0.5 μM). The cells were 
harvested after another 24 hours and Western blot was performed to determine the protein 
levels of PTBP1, PARP, cleaved caspase 3 and BIM. Equal loading in each lane was 




4.6 HNRNP H AND HNRNP F DO NOT REGULATE SPLICING OF BIM EXON 3 
 
 I next investigated trans-acting factors that regulate exon 3 splicing via the 23-nt ISS 
which I have identified earlier (Figure 37). Examination of the 23-nt ISS revealed that this 
sequence contains two poly-uridine tracts and a GGGG motif (Figure 43a). Previous studies 
have shown that hnRNP C associates with poly-uridine tracts182, whereas hnRNP F and 
hnRNP H are two closely related proteins that associate with GGGG motifs168. In addition, 
computational analysis also predicted that hnRNP F/H and hnRNP C binds to the GGGG 
motif and the poly-uridine tracts, respectively. Therefore, the 23-nt ISS may cause skipping of 
BIM exon 3 by interacting with hnRNP C, hnRNP F and hnRNP H. 
To address this possibility, I mutated the two poly-uridine tracts and the GGGG motif 
within the 23-nt ISS and assessed whether these mutations have an effect on exon 3 inclusion 
(Figure 43b). Strikingly, mutating the two poly-uridine tracts and the GGGG motif (Δ10F4) 
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led to an increase in exon 3 inclusion when compared to Δ10F. Importantly, the extent of 
exon 3 inclusion was similar when compared to the Δ10F3 minigene, which has the 23-nt ISS 
removed (Figure 43b). This observation suggests that the poly-uridine tracts and the GGGG 
motif are critical elements within the ISS that repress inclusion of exon 3.                                     
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Figure 43: Mutating the GGGG motif and the poly-uridine tracts within the ISS  
enhances the inclusion of exon 3. (a) Schematics of the Δ10, Δ10F, Δ10F3 and Δ10F4  
minigenes. The poly-uridine tracts and the GGGG motif in Δ10F are underlined. Removal of 
the 23-nt ISS in Δ10F3 is indicated by dashes. Point mutations in Δ10F4 that disrupt the poly- 
uridine tracts and the GGGG motif are indicated in red. (b) K562 cells were nucleofected with  
1 μg of minigenes. RNA was isolated 24 hours later and real-time RT-PCR was performed to  
assess the expression of minigene products that contain either BIM exon 3 or exon 4. The Δ11  
minigene served as a positive control for enhanced exon 3 inclusion.  Experiments were  
performed in triplicates and the relative E3: E4 ratio was determined by normalizing to the  
E3: E4 ratio of K562 cells that were nucleofected with the Δ10 minigene. Error bars represent  





Since mutating the GGGG motif enhances the inclusion of BIM exon 3, I next sought 
to test whether hnRNP F and hnRNP H were involved in the splicing of exon 3. Depletion of 
hnRNP F and hnRNP H were performed using two different siRNA duplexes for each protein 
to address concerns about off-target effects. All siRNA treatments were effective at reducing 
the transcript levels of the targeted protein by at least 3-fold when compared to cells that were 
nucleofected with the control siRNA (Figure 44a,b). Western blotting was also performed to 
show that hnRNP H protein levels were decreased after nucleofection with hnRNP H-specific 
siRNA duplexes (Figure 44c). Interestingly, one of the siRNAs targeting hnRNP F (siF2) led 
to a slight upregulation of hnRNP H transcripts, which may suggest that knockdown of 
hnRNP F may cause a compensatory upregulation of hnRNP H (Figure 44a). Analysis of the 
ratio of exon 3- to exon 4-containing endogenous BIM transcripts did not show an enhanced 
exon 3 inclusion when either hnRNP F or hnRNP H was depleted (Figure 44d). Surprisingly, 
when hnRNP F and hnRNP H were depleted together, I observed a modest decrease in exon 3 
inclusion when compared to cells that were nucleofected with the control siRNA (Figure 44d). 
Taken together, these results demonstrate that hnRNP F and hnRNP H may not function as 












































































Figure 44: Silencing of hnRNP H and hnRNP F does not lead to an increase in  
endogenous BIM exon 3 inclusion. K562 cells were nucleofected with two different siRNA  
duplexes targeting either hnRNP F (siF1, siF2) or hnRNP H (siH1, siH2). Some cells were  
also nucleofected with siRNA duplexes targeting both hnRNP F and hnRNP H (siF1 and 
siH1, siF2 and siH2) to silence both proteins. 48 hours post-nucleofection, RNA was isolated  
from these cells and real-time RT-PCR was performed to measure the relative expression of  
(a) hnRNP H and (b) hnRNP F transcripts. “U” represents control cells that were not 
 subjected to nucleofection. Experiments were performed in triplicates and data is shown as  
mean ± standard error of the mean relative to cells that were not nucleofected. (c) Western  
blot showing the efficacy of the two siRNA duplexes targeting hnRNP H. Protein bands  
shown were from different lanes but within the same membrane. (d) Ratio of endogenous BIM  
transcripts containing exon 3 over exon 4 after nucleofecting cells with the indicated siRNAs.  
“U” represents control cells that were not subjected to nucleofection. Experiments were  
performed in triplicates and the relative E3: E4 ratio was determined by normalizing to the  









4.7 THE ROLE OF HNRNP C IN REPRESSING THE INCLUSION OF BIM EXON 3 
 
 Because mutating the poly-uridine tracts within the ISS promote the inclusion of BIM  
 
exon 3, I next sought to test whether hnRNP C is involved in the splicing of exon 3 since  
 
hnRNP C is known to associate with poly-uridine tracts. Three different siRNA duplexes 
 
specific for hnRNP C were used to deplete hnRNP C protein levels. All three siRNA duplexes  
 
were effective at decreasing both isoforms of hnRNP C (hnRNP C1 and hnRNP C2)  
 
significantly (Figure 45a). I also observed a significant inclusion of endogenous BIM exon 3  
 
upon silencing of hnRNP C (Figure 45b). Collectively, these results suggest that hnRNP C  
 



































Figure 45: Inclusion of endogenous BIM exon 3 was promoted upon depletion of hnRNP  
C. (a) Western blot showing the efficacy of the three siRNA duplexes (si1, si2, si3)  
targeting hnRNP C after they were introduced into K562 cells. Protein bands shown were  
from different lanes but within the same membrane. (b) RNA was isolated from K562 cells 48  
hours post-nucleofection. Real-time RT-PCR analysis was performed to assess the ratio of  
endogenous BIM transcripts containing either exon 3 or exon 4. Experiments were  
performed in triplicates and the relative E3: E4 ratio was determined by normalizing to the  
E3: E4 ratio of K562 cells that were not nucleofected. Error bars represent ± standard error of  




 Next, I investigated whether hnRNP C promotes the exclusion of BIM exon 3 via the 
poly-uridine tracts and the GGGG motif within the 23-nt ISS. To this end, I silenced the 
expression of hnRNP C using siRNA (si1) and then nucleofected K562 cells with either the 
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Δ10F or the Δ10F4 minigene (Figure 46a). Inclusion of exon 3 was increased by at least 10-
fold when K562 cells were nucleofected with the Δ10F minigene after hnRNP C was depleted 
when compared to cells that were nucleofected with the control siRNA. However, this effect 
was not significantly reduced when K562 cells were nucleofected with the Δ10F4 minigene 
which harbor mutations within the poly-uridine tracts and the GGGG motif (Figure 46b). 
Taken together, these results indicate that hnRNP C regulates the inclusion of BIM exon 3 but 
these effects may or may not be mediated in part by the 23-nt ISS as there could be more 
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Figure 46: Mutating the poly-uridine tracts and the GGGG motif within the 23-nt ISS  
does not lead to a significant reduction in BIM exon 3 inclusion after depleting hnRNP  
C. (a) Schematics of the Δ10F and the Δ10F4 minigenes. Point mutations within the ISS are  
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shown in red. (b) K562 cells were nucleofected with either the control or the hnRNP C- 
specific siRNA duplexes (si1). 24 hours later, these cells were nucleofected with the Δ10F or  
the Δ10F4 minigene. RNA was isolated after another 24 hours and real-time RT-PCR was  
performed to determine the ratio of minigene products containing exon 3 over exon 4.  
Experiments were performed in triplicates and the relative E3: E4 ratio was determined by  
normalizing to the E3: E4 ratio of K562 cells nucleofected with the same minigene, but  




The effects of downregulating hnRNP C on imatinib-induced apoptosis were also  
 
investigated. However, unlike PTBP1, siRNA-mediated knockdown of hnRNP C promoted  
 
the induction of imatinib-induced apoptosis as indicated by the increased expression of  
 
cleaved PARP and cleaved caspase 3 when compared to K562 cells that were nucleofected  
 
with the control siRNA (Figure 47). Intriguingly, downregulation of hnRNP C promoted the  
 
induction of BIML and BIMS upon treating K562 cells with increasing doses of imatinib  
 
(Figure 47), even though knockdown of hnRNP C enhanced the inclusion of exon 3- 
 
containing BIM transcripts over exon 4 (Figure 45b). These observations will be elaborated on  
 












hnRNP C siRNA 2






Figure 47: Downregulation of hnRNP C does not inhibit imatinib-induced apoptosis.  
K562 cells were nucleofected with either control or hnRNP C-specific siRNA duplexes. 24  
hours later, these cells were treated with increasing doses of imatinib (0, 0.25, 0.5 μM). The  
cells were harvested after another 24 hours and western blot was performed to determine the  
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protein levels of PTBP1, PARP, cleaved caspase 3 and BIM. Equal loading in each lane was  
determined by assessing the expression of GAPDH.  
 
 
4.8 THE IDENTIFICATION OF TRANS-ACTING FACTORS THAT BIND TO THE 
23-NT INTRONIC SPLICING SILENCER USING RNA PULL-DOWN ASSAY 
 
 Since I was not successful in predicting splicing factors that regulate BIM exon 3 
inclusion via the 23-nt ISS, I performed RNA pull-down to identify RNA-binding proteins 
that interact with the 23-nt ISS. A RNA harboring the entire 23-nt ISS (Figure 48a; 10F) was 
used as a bait to pull-down interacting proteins. Here, beads coated with the 10F RNA were 
incubated with nuclear extract from K562 cells. To control for non-specific binding, I used a 
RNA that harbored point mutations within the 23-nt ISS which disrupted the poly-uridine 
tracts and the GGGG motif (Figure 48a; 10F4), as well as another RNA that contained an 
inversion of the 23-nt ISS (Figure 48a; 10F3inv). After multiple washes, RNA-associated 
proteins were eluted and resolved by gel electrophoresis. Subsequently, silver staining was 
performed to visualise the gel. Three protein bands (Figure 48b; Bands A, B, C) were found to 
bind more abundantly to the 10F RNA than the 10F4 and the 10F3inv RNAs. Mass 
spectrometry analysis revealed that band A contained several proteins such as the splicing 
regulator, KH-type splicing regulatory protein (KHSRP), and a hypothetical protein that is 
similar to splicing factor 1 (SF1). Surprisingly, hnRNP H and hnRNP F were candidate 
proteins that bind to the 23-nt ISS (Figure 48c; Band C), even though downregulation of 
hnRNP H and hnRNP F did not enhance exon 3 inclusion (Figure 44d). Protein band B was 
not sent for analysis because the band was not well-resolved.  
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Figure 48: Identification of trans-acting factors that bind to the 23-nt ISS using RNA 
pull-down and mass spectrometry analysis. (a) Schematics of the 10F, 10F4 and 10F3inv 
RNAs. The 23-nt ISS is shown in red. Point mutations that disrupt the poly-uridine tracts and 
the GGGG motif are indicated in green. An inversion of the 23-nt ISS is indicated in blue. (b) 
RNA pull-down analysis using 10F, 10F4 and 10F3inv RNAs. RNA-bound proteins were 
eluted from the beads and resolved by gel electrophoresis. Silver staining was performed to 
visualise the gel. The three protein bands (A, B, C) that bind more abundantly to the 10F RNA 
were marked with red arrowheads. (c) Mass spectrometry analysis of protein bands A and C. 
Note: Identification of protein bands A and C was performed by The Proteomic Core 





To evaluate whether KHSRP, hnRNP H and hnRNP F truly interacted with the 23-nt 
ISS, I performed Western blot on the eluted RNA-associated proteins from the pull-down 
assay using antibodies against KHSRP, hnRNP H and hnRNP F. HnRNP H and hnRNP F 
interacted with the 10F RNA, which does not contain any mutations within the 23-nt ISS. 
This interaction was abolished when I used either the 10F4 or the 10F3inv RNA for the pull-
down. In contrast, KHSRP was not able to interact with the 10F RNA (Figure 49). Taken 
together, these results indicate that hnRNP H and hnRNP F, but not KHSRP, interact with the 
23-nt ISS and that this interaction is dependent on the GGGG motif and the poly-uridine tracts 
within the ISS. It is intriguing that hnRNP H and hnRNP F does not repress exon 3 inclusion 





           









Figure 49: The 23-nt ISS interacts with hnRNP H and hnRNP F, but not KHSRP. RNA 
pull-down assay with K562 nuclear extracts with the indicated RNA probes. RNA-bound 
proteins were analyzed by Western blot with antibodies against hnRNP H, hnRNP F and 
KHSRP. Note: The Western blot on the eluted RNA-associated proteins was performed by 




4.9 CONCLUSION (PART 2) 
 
In silico analysis predicted that PTBP1, hnRNP F, hnRNP H and hnRNP C repress 
inclusion of BIM exon 3 via the deleted fragment. RNA pull-down assay demonstrated that 
hnRNP H and hnRNP F interact with the 23-nt ISS. However, using siRNAs to downregulate 
hnRNP H and hnRNP F, I showed that hnRNP H and hnRNP F do not repress exon 3 
inclusion. Silencing of PTBP1 demonstrated that PTBP1 represses the inclusion of BIM exon 
3. However, PTBP1-mediated repression of exon 3 inclusion does not appear to depend on the 
2,903-nt deleted fragment. Knockdown of hnRNP C confirmed that hnRNP C is another 
splicing factor that represses endogenous BIM exon 3 inclusion. Yet, the effects of hnRNP C 
on exon 3 exclusion may or may not be dependent on the 23-nt ISS. Functionally, 
downregulation of PTBP1, but not hnRNP C, impaired induction of imatinib-induced 
apoptosis. Further analysis is required to identify splicing factors that repress exon 3 inclusion 












5.1 THE BIM DELETION POLYMORPHISM AS A BIOMARKER FOR TKI-
RESISTANCE IN KINASE-DRIVEN CANCERS 
 
 Despite the success of TKIs in the treatment of kinase-driven cancers, most of these 
tumors are not completely eradicated, and hence, patients remain at risk of relapse. As a 
result, there is a huge focus in research to study somatically acquired mutations in the tumor 
cells that drive disease progression and drug resistance. In this thesis, I have shown that apart 
from somatic changes in tumor cells, germline polymorphisms can also play an important role 
in influencing a patient’s response to TKIs. Notably, I have shown that a common deletion 
polymorphism in a pro-apoptotic member of the BCL-2 family, BIM, can have an important 
role in the response to TKIs in kinase-driven cancers such as CML and EGFR NSCLC. This 
polymorphism alters the splicing of BIM, resulting in the preferential expression of BIM 
proteins that lacked the pro-apoptotic BH3 domain. As a result, individuals with the BIM 
deletion polymorphism are more likely to respond poorly to TKIs. I proposed that the BIM 
polymorphism could influence the response to TKIs in other kinase-driven cancers that rely 
on the upregulation of BIM expression for the induction of apoptosis. Such cancers would 
include human epidermal growth factor receptor 2-driven breast cancers183 as well as c-KIT-
dependent gastrointestinal stromal tumors184.  
 The BIM deletion polymorphism appears to be present only in East Asian populations, 
with around 12.3% of East Asians harboring the polymorphism (Table 2). Curiously, it has 
been reported that East Asian patients have a lower rate of complete cytogenetic response to 
imatinib (approximately 50%) when compared to CML patients from Europe and North 
America (74%)185. The findings from this thesis suggest that the poorer response observed in 
East Asian populations could be attributed at least in part by the BIM deletion polymorphism.  
 Interestingly, seven individuals with CML were sensitive to imatinib even though 
they are carriers of the BIM deletion polymorphism (Table 3). This observation is not 
unexpected given that apoptotic signaling is extremely complex, so different mechanisms may 
exist which could restore apoptotic signaling even though these individuals harbor the BIM 
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deletion polymorphism. Therefore, other factors, including acquired and germline variants as 
well as the tumor microenvironment, have to be considered before we can effectively predict 
whether a patient will have a good response to TKIs. Indeed, several mechanisms of BCR-
ABL1-independent resistance have been reported, including signaling from the bone marrow 
microenvironment96, activated c-RAF186 and overexpression of SRC family kinases83.  
 Employing the BIM deletion polymorphism as a predictive marker can be more 
advantageous compared to the use of acquired mutations as biomarkers. First, because the 
BIM deletion polymorphism is a germline variant, therefore, it can be found in every single 
cell within the body. As a result, the BIM polymorphism can be screened in a non-invasive 
manner simply by obtaining a blood sample or performing a buccal swap from the patient. In 
contrast, acquired mutations are only present within the tumor cells and hence, obtaining these 
samples can be more invasive especially if the tumor is present within the body. Furthermore, 
the detection of acquired mutations could be masked by the presence of “normal” DNA from 
neighbouring non-malignant cells that are extracted together with the malignant cells. Second, 
acquired mutations are usually detected at the later stage of the disease, which may not be 
beneficial to the patient as he or she may already have developed resistance to TKIs. 
However, germline biomarkers can be screened at the early stage of the disease. This would 
allow the early use of drug combinations, such as TKIs and BH3-mimetics, for maximal 
tumor cell-killing before the emergence of drug resistant clones.  
 Finally, an important lesson can be learnt from the discovery of the BIM deletion 
polymorphism. Often in cancer genomics, researchers focus on somatically acquired 
mutations (missense and nonsense) in the coding sequence of the gene. Therefore, pipelines 
have been developed to remove germline mutations from the analysis. In addition, mutations 
that occur in the non-coding region of the gene, such as the introns, are usually not at the 
highest priority for functional studies. This method for selecting target mutations for 
functional analysis is considered conventional because somatic mutations that directly affect 
the protein structure are more likely to result in a functional change that drive disease 
progression and modulate drug response. However, the findings from this thesis suggest that 
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germline variations in the non-coding region of a gene, such as the BIM deletion 
polymorphism, could influence a patient’s response to TKIs as well by affecting gene 
expression such as pre-mRNA splicing. Therefore, the analysis of the cancer genome should 
not exclude polymorphisms as well as mutations in the non-coding regions especially for 
genes that have been shown to play a major function in cancer.  
 
5.2 OTHER POTENTIAL IMPLICATIONS OF THE BIM DELETION 
POLYMORPHISM IN HUMAN DISEASES 
 
 The observation that the BIM deletion polymorphism is a common germline variant 
suggests that it may confer an evolutionary advantage to carriers harboring the deletion. 
Previous reports have demonstrated that immune response was not terminated in Bim-
deficient mice after infection with the herpes simplex virus and there was an accumulation of 
CD8+ T cells in the spleen187. These observations suggest that BIM is required for the 
induction of apoptosis in T cells during the termination of an immune response. Because the 
induction of BH3-containing BIM isoforms is impaired in cells harboring the BIM deletion 
polymorphism, I speculate that individuals who harbor the BIM polymorphism may have a 
more sustained immune response which could allow them to combat certain viral infections 
more effectively than individuals with the wild-type BIM allele.  
 Interestingly, Bim is also required for apoptosis of autoreactive T cells during T cells 
development in the thymus188. This observation suggests that individuals with the BIM 
polymorphism could be predisposed to the development of autoimmune diseases. In addition, 
mice that lacked a single Bim allele were also prone to the development of Myc-induced B 
cell leukemia, suggesting that Bim could function as a tumor suppressor189. Based on these 
results, we propose that individuals harboring the BIM deletion polymorphism may also be at 
risk of developing certain cancers due to the lower expression of functional BIM proteins. We 
are planning to generate humanized Bim mice, with and without the BIM deletion 
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polymorphism, to address whether the polymorphism plays a role in the development of these 
diseases.  
 
5.3 ALTERNATIVE APPROACHES TO OVERCOME TKI-RESISTANCE 
ASSOCIATED WITH THE BIM DELETION POLYMORPHISM 
 
 Although the use of TKIs as a single agent has been relatively successful for the 
treatment of kinase-driven cancers, the quality and duration of these responses are still 
heterogenous. This suggests that there are other genetic (germline and somatically acquired 
mutations), epigenetic, as well as microenvironmental factors that play important roles in 
modulating a patient’s response to TKIs. Therefore, the study of rational drug combinations is 
an important strategy to achieve maximal killing of tumor cells.  
 In this thesis, I have shown that TKI-resistance associated with the BIM deletion 
polymorphism, as a result of impaired upregulation of BH3-containing BIM proteins, can be 
overcome by re-expression of BIMEL (Figure 22). Therefore, we hypothesized that a rational 
approach to overcome TKI-resistance is to employ BH3-mimetics together with TKIs. Indeed, 
sensitivity towards TKIs was restored when we treated polymorphism-containing CML and 
EGFR NSCLC cell lines with ABT-737 together with TKIs (Figures 23 and 29). However, a 
major weakness of ABT-737 is its inability to interact with the pro-survival protein, MCL-
1190. Indeed, a group have reported that ABT-737 is not efficient at inducing apoptosis in 
tumor cells expressing elevated levels of MCL-1191. Therefore, we hypothesized that the use 
of ABT-737 together with TKIs to overcome resistance associated with the BIM deletion 
polymorphism may not be effective if the individual expresses elevated levels of MCL-1.  
 An alternative approach to overcome resistance associated with the BIM 
polymorphism is to employ a pan-BCL-2 inhibitor such as sabutoclax, which can interact and 
inhibit all pro-survival members of the BCL-2 family192. The use of sabutoclax appears to be a 
useful approach for the treatment of CML as it has been shown that sabutoclax can assist 
TKIs in the elimination of leukemia stem cells193.  
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 Another strategy to overcome resistance due to the BIM deletion polymorphism is to 
find means to upregulate endogenous BH3-containing BIM proteins. Upregulating BIM 
expression is an attractive strategy because not only is BIM able to inhibit all pro-survival 
members of the BCL-2 family, it is also able to activate BAX and BAK directly to trigger the 
release of cytochrome c194. Recently, a group has demonstrated that histone deacetylase 
inhibitors can increase the expression of BH3-containing BIM proteins. Furthermore, they 
have also shown that the combination of histone deacetylase inhibitors and gefitinib can 
overcome resistance associated with the BIM deletion polymorphism in EGFR NSCLC cell 
lines195.  
The use of antisense oligonucleotides (ASOs) to correct the aberrant pre-mRNA 
splicing to favor exon 4-containing BIM transcripts is another approach to increase the 
expression of BH3-containing BIM proteins. This can be done by designing ASOs that bind to 
the 3’ splice site of BIM exon 3 or to other cis-regulatory elements that promote inclusion of 
exon 3. Successful application of ASOs would redirect the splicing machinery to the 3’ splice 
site of exon 4 so that exon 4 can be included into the transcript instead.  
 Duchenne Muscular Dystrophy (DMD) is a X-linked recessive neuromuscular disease 
that is caused by mutations in the gene that encodes for dystrophin196; 197. These mutations 
affect the open reading frame, which lead to premature termination of translation. The 
truncated protein could not be detected in patients, suggesting that it is unstable198. A strategy 
to treat DMD is to develop ASOs to induce skipping of a key exon that would restore the 
reading frame of the dystrophin transcript so that the dystrophin protein can be expressed. 
Two recent Phase I/II clinical trials in patients with DMD have provided critical evidence that 
systemically administered ASOs are able to induce exon skipping in the striated muscle of 
patients, leading to the restoration of dystrophin expression199; 200. These proof-of-concept 
studies show that therapeutic ASOs can overcome many of the initial pitfalls of first-
generation ASOs, which include: enhanced serum stability, resistance to nuclease degradation, 
and ability to achieve nuclear concentrations sufficient for a biological effect on splicing200. 
Collectively, these promising findings indicate that there is a huge potential for the use of 
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ASOs to restore aberrant splicing of BIM to produce BH3-containing BIM proteins that could 
restore sensitivity to TKIs among patients with the BIM deletion polymorphism.  
 
5.4 THE ROLE OF POLYMORPHISMS IN SPLICING-RELATED DISEASES  
 
 Genetic diseases are caused by DNA mutations that have a direct impact on protein 
structure by changing the amino acid sequence or disrupting regulatory elements that are 
critical for regulating gene expression201. It has been predicted that approximately 50% of all 
disease-causing point mutations are believed to be deleterious by affecting pre-mRNA 
splicing202. These mutations disrupt alternative splicing by affecting the essential splicing 
elements, such as the splice sites, or the intronic/exonic splicing enhancers or silencers203. 
Apart from point mutations, structural variations, such as deletions, insertions and inversions, 
have also been shown to affect alternative splicing as well. For example, an in-frame 3-bp 
deletion in exon 10 of the microtubule-associated protein tau gene can cause frontotemporal 
dementia with parkinsonism by disrupting an exonic splicing enhancer204.  
 Recently, there is growing evidence demonstrating that common polymorphisms, 
especially SNPs, can modulate pre-mRNA splicing205. It has been estimated that around 20% 
of alternatively spliced genes demonstrate evidence of allele-specific splicing206. A salient 
example of this is the causal SNP C > T (rs6897932) located within exon 6 of the gene 
encoding for interleukin 7 receptor alpha chain (IL7R) that is functionally associated with 
multiple sclerosis207.  IL7R is a transmembrane receptor that maintains survival of T-cells 
upon binding with the ligand, interleukin 7208. The transmembrane domain of IL7R is encoded 
in exon 6 and it has been demonstrated that the disease-associated C allele resulted in the 
preferential skipping of exon 6 compared with transcripts that harbor the T allele207. These 
results strongly argue for the hypothesis that individuals carrying the C allele at rs6897932 
produce more IL7R that is soluble which could be linked to the development of multiple 
sclerosis.  
 Some SNPs are associated with an increased risk of cancer development by altering 
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pre-mRNA splicing of tumor suppressors and oncogenes. Kruppel-like factor 6 (KLF6), a 
Kruppel-like zinc finger transcription factor, functions as a tumor suppressor via p21 to inhibit 
cell proliferation209. KLF6-SV1, a splice variant of KLF6, functions as a dominant negative 
isoform of KLF6 that enhances cell proliferation and cell migration210. Recently, a SNP in 
KLF6 is found to be associated with an increased risk of prostate cancer in men. In addition, 
this SNP creates a splicing enhancer element for the binding of SRSF5 and this is associated 
with a preferential expression of KLF6-SV1 over KLF6211. Collectively, these results suggest 
that polymorphisms within splicing regulatory elements of tumor suppressors and oncogenes 
can influence the risk of developing cancer.  
However, little is known about polymorphic structural variations affecting splicing 
and disease risks in humans, although a small deletion polymorphism in the ATP13A2 gene 
was found to be associated with a progressive neurodegenerative disease in dogs212. In this 
thesis, I have shown that a common deletion polymorphism within intron 2 of the BIM gene 
mediates intrinsic resistance towards TKIs by favoring the expression of BIM proteins that 
lack the pro-apoptotic BH3 domain. Therefore, this work emphasizes the importance of 
studying polymorphic structural variations in human diseases as well. I proposed that the 
study of polymorphic structural variations is equally, if not, more important than the study of 
SNPs in human diseases. This is because, unlike SNPs, the likelihood of disrupting a 
regulatory element is higher for polymorphic structural variations since they affect a larger 
segment of the DNA sequence. 
 
5.5 REGULATION OF BIM EXON 3 SPLICING VIA THE BIM DELETION 
POLYMORPHISM  
 
 By performing a forward and a reverse deletion analysis to identify cis-regulatory 
elements that repress inclusion of BIM exon 3, I have demonstrated that there are numerous 
redundant elements within the 2,903-nt deleted fragment that repress splicing of exon 3 
(Figure 32). In addition, I have also shown that a 322-nt sequence at the 3’ end of the deletion 
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(+2,582 to +2,903) harbors regulatory elements that are sufficient but not necessary for 
repressing exon 3 inclusion (Figure 32). Further analysis revealed that +2,582 to +2,662 and 
+2,823 to +2,903 within this 322-nt region contain most of the elements at the 3’ end of the 
deletion that repress inclusion of exon 3 (Figure 35). 
 It has been shown that RNA secondary structures may cause cis-regulatory elements 
to become inaccessible to splicing factors. As a result, RNA secondary structures could 
promote exon skipping213. Since +2,582 to +2,662 and +2,823 to +2,903 of the BIM intronic 
deletion are present at close proximity with each other and furthermore, they are close to the 
3’ splice site of exon 3, it is possible that these two regions may form a secondary structure 
that could impair inclusion of BIM exon 3. If this is the case, removing +2,582 to +2,662 or 
+2,823 to +2,903 of the BIM intronic deletion from the Δ10 minigene should abolish the 
secondary structure and hence, lead to a significant increase in the minigene products 
harboring exon 3. However, partial and complete removal of +2,582 to +2,662 or +2,823 to 
+2,903 of the deletion (Figure 34, MUT1 and MUT5 minigenes; Figure 35, Δ10A and Δ10B 
minigenes) fail to cause a significant increase in the inclusion of exon 3. These results argue 
against the hypothesis that +2,582 to +2,662 and +2,823 to +2,903 of the BIM intronic 
deletion form a secondary structure that could inhibit inclusion of exon 3.  
Computational analysis predicted that there are three putative binding sites for the 
splicing repressor, PTBP1, within +2,582 to +2,662 of the deletion. In addition, a study in 
HeLa cells has also shown that PTBP1 could interact with the deleted fragment at position 
+1,084 to +1,100179, suggesting that PTBP1 could repress inclusion of BIM exon 3 by binding 
to sequences within the 2,903-nt deleted fragment. Indeed, knockdown of PTBP1 led to a 
significant 2-fold increase in the ratio of endogenous BIM transcripts containing exon 3 over 
exon 4 (Figure 40), indicating that PTBP1 functions as a repressor of exon 3 inclusion. 
Surprisingly, removing the three putative PTBP1 binding sites from +2,582 to +2,662 of the 
deletion does not lead to a significant increase in the expression of minigene products 
harboring exon 3 (Figure 36). Furthermore, silencing PTBP1 expression followed by 
expressing a minigene that only contain +2,582 to +2,662 of the deletion, (Figure 41, Δ10E) 
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does not lead to a significant increase in exon 3 inclusion. These results indicate that PTBP1 
does not regulate exon 3 inclusion via +2,582 to +2,662 of the deletion. I speculated that 
perhaps PTBP1 regulate exon 3 inclusion via other regions of the deleted fragment such as 
position +1,084 to +1,100. However, silencing PTBP1 expression followed by expressing the 
WT minigene, which harbors the entire 2,903-nt polymorphic fragment, also did not lead to a 
significant increase in exon 3 inclusion (Figure 41). Because these minigenes do not contain 
all the cis-elements in introns 2 and 3, our results suggest that PTBP1 regulates splicing of 
BIM exon 3 via other cis-acting elements within BIM, at least in K562 cells. Besides PTBP1’s 
role in regulating pre-mRNA splicing, PTBP1 has also been implicated in the regulation of 
cap-independent translation mediated by the internal ribosomal entry site214; 215. Therefore, it 
is also possible that PTBP1 could repress exon 3 inclusion indirectly by regulating the 
expression of other splicing factors.  
Functionally, downregulation of PTBP1 impaired induction of imatinib-induced 
apoptosis and this is associated with decreased induction of BH3-containing BIM proteins 
(Figure 42). These results suggest that reduced expression of PTBP1 may be a useful 
biomarker to predict for a poorer response to TKIs in cancer. Interestingly, a recent report 
showed that downregulation of PTBP1 sensitizes ovarian cancer cells to chemotherapeutic 
agents such as carboplatin or paclitaxel216. These findings are somewhat contradictory to what 
we observed when we downregulated PTBP1 in CML cells. These conflicting observations 
could be accounted for by the fact that splicing regulation can occur in a tissue-specific 
manner due to differential expression of splicing factors in different tissues217. Therefore, 
downregulation of PTBP1 in ovarian cancer cells may not lead to changes in the splicing of 
BIM exons 3 and 4.  
Deletion analysis on +2,823 to +2,903 of the deleted fragment revealed a 23-nt ISS 
that is critical for the silencing of BIM exon 3 (Figure 37). Computational analysis predicted 
that hnRNP C and hnRNP F/H could regulate inclusion of exon 3 by associating with the 
poly-uridine tracts and the GGGG motif present within the ISS, respectively. Surprisingly, 
silencing both hnRNP F and hnRNP H did not enhance endogenous BIM exon 3 inclusion 
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(Figure 44). Although silencing of hnRNP C enhanced endogenous exon 3 inclusion (Figure 
45), the results still remain inconclusive on whether hnRNP C regulates exon 3 repression via 
the 23-nt ISS (Figure 46). Interestingly, downregulation of hnRNP C enhanced imatinib-
induced apoptosis and promoted the induction of BIML and BIMS (Figure 47). Because 
hnRNP C binds to and regulates the splicing of numerous other pre-mRNAs182, we speculate 
that the overall effect of downregulating hnRNP C could promote the expression of other 
splice variants that can sensitize CML cells to imatinib-induced apoptosis. 
 Computational analysis does not reliably predict the role of splicing factors. Some of 
the limitations are due to the fact that most algorithms do not take into account secondary and 
tertiary RNA structures, which will influence the ability of splicing factors to associate with 
their cognate binding sites. Secondly, pre-mRNA splicing is a complex process that involves 
numerous splicing signals with other trans-acting factors that are usually not accounted for in 
prediction software. Finally, the number of experimentally validated linear sequences that are 
used to write these programs are limited. As a result, prediction programs are at best a tool for 
hypothesis generation.  
 RNA pull-down followed by mass spectrometry analysis revealed that the 23-nt ISS 
could potentially bind to KHSRP, hnRNP F and hnRNP H (Figure 48). An earlier study has 
shown that KHSRP promotes the assembly of numerous proteins to regulate the inclusion of 
the neuron-specific c-src N1 exon218. Therefore, it is possible that KHSRP could bind to the 
23-nt ISS to repress inclusion of BIM exon 3. However, Western blot analysis could only 
verify the interaction of hnRNP H and hnRNP F with the 23-nt ISS, but not KHSRP (Figure 
49). Since protein band A is unlikely to be KHSRP, I speculate that protein band A could be 
the hypothetical protein similar to SF1 that was also identified by mass spectrometry analysis 
(Figure 48). Protein band A could also be far upstream element binding protein 1 (FUBP1), 
which is a 68 kDa protein that has a 70% amino acid sequence identity with KHSRP218. It is 
also intriguing that hnRNP H and hnRNP F interacted with the 23-nt ISS, but yet it does not 
function as a repressor of exon 3 inclusion because downregulation of hnRNP H and hnRNP 
F did not enhance inclusion of BIM exon 3 (Figure 44). There are two possible answers to 
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this: (1) HnRNP H/F may be functionally redundant in repressing exon 3 inclusion; and (2) 
downregulation of hnRNP H/F could activate a compensatory mechanism which prevents 
inclusion of BIM exon 3.  
There are several important questions left unanswered from this thesis. Firstly, does 
FUBP1 and SF1 bind to the 23-nt ISS to repress exon 3 inclusion? To answer this question, 
we plan to perform Western blot on the eluted RNA-associated proteins from the RNA pull-
down assay using antibodies against FUBP1 and SF1. In addition, we also plan to 
downregulate FUBP1 and SF1 using siRNAs and nucleofect cells with the Δ10F and Δ10F4 
minigenes to assess whether these proteins regulate the inclusion of BIM exon 3 via the poly-
uridine tracts and the GGGG motif within the 23-nt ISS. Secondly, could reduce expression of 
PTBP1 serve as a biomarker? To establish the feasibility of PTBP1 as a biomarker, more 
work is required to determine whether decreased expression of PTBP1 is associated with a 
poorer response to TKIs in CML and EGFR NSCLC. Finally, are there additional DNA 
biomarkers that could predict aberrant splicing of BIM ? We asked this question because the 
UCSC Genome Browser indicated that there are at least 13 SNPs within the 2,903-nt 
polymorphic fragment. Since SNPs could influence pre-mRNA splicing, it would be 
interesting to investigate whether SNPs within the 2,903-bp intronic sequence have any effect 























Ethics committee approval 
Clinical CML samples were collected from patients seen at the Singapore General 
Hospital (Singapore), University of Malaya Medical Centre (Malaysia), National University 
Cancer Institute (Singapore) and Akita University Hospital (Japan). Non-diseased individuals 
from Germany were obtained from blood donors at the University Hospital of Bonn. Chinese, 
Malay and Indian control samples were obtained from local population studies219; 220 to assess 
the population frequency of the BIM deletion polymorphism. We acquired clinical NSCLC 
samples from patients seen at the Toho University Omori Medical Center (Japan), Aichi 
Cancer Center (Japan), National Cancer Centre (Singapore) and the National University 
Cancer Institute, National University Health System (Singapore). All clinical samples were 
collected from consenting patients and healthy individuals after obtaining approval from the 
institutional review board. 
 
Cell lines, culture and drugs 
CML and NSCLC cell lines were obtained from American Type Culture Collection 
(MEG-01, KU812, H520, H820, HCC4006 and H1299), Japanese Collection of Research 
Bioresources (NCO2) and German Collection of Microorganisms and Cell Cultures (K562, 
KCL22, KYO-1, BV173, JK1 and NALM1). The NSCLC cell lines, PC9, HCC2279 and 
HCC2935 were gifts from Dr Philip Koeffler. These cells were cultured in RPMI-1640 culture 
medium (Gibco) supplemented with penicillin/streptomycin (Hyclone), glutamine (Hyclone), 
10% (v/v) fetal bovine serum (Hyclone), and were incubated in a humidified incubator at 
370C with 5% CO2. Genome-edited K562 and PC9 cells were cultured in RPMI-1640 medium 
containing penicillin/streptomycin, glutamine and 20% (v/v) fetal bovine serum. All drugs 
were dissolved in DMSO [50% (v/v) DMSO for imatinib; 100% (v/v) DMSO for gefitinib, 





Identification of structural variations by DNA-PET sequencing 
 DNA-PET sequencing and clustering of discordant PETs for detection of structural 
variations in our clinical samples and the K562 cells has been described previously in Hillmer 
et al. (2012)128. The SOLiD platform (Applied Biosystems) was used to sequence the DNA-
PET libraries of 5, 7, and 9-kb DNA fragments. Sequencing data from this project have been 
submitted to NCBI Gene Expression Omnibus at http://www.ncbi.nlm.nih.gov/geo. Data for 
the five CML patient samples is under the accession number GSE28303, whereas data for the 
K562 cell line is under the accession number GSE26954. Note: DNA-PET sequencing and 
identification of structural variations were performed by Dr Axel Hillmer and staff from the 
Genome Institute of Singapore, Singapore.  
  
Genotyping individuals for the BIM deletion polymorphism 
Determination of patient’s genotype: 
 We extracted genomic DNA from either patients’ peripheral blood (CML and NSCLC 
patients) or from formalin-fixed paraffin-embedded (FFPE) biopsy slides obtained from 
NSCLC patients. A single PCR reaction was performed to genotype genomic DNA from 
peripheral blood using JumpStart RedAccuTaq LA DNA polymerase (Sigma) with the 
forward primer 5’-AATACCACAGAGGCCCACAG-3’ and the reverse primer 5’-GCCTGA- 
AGGTGCTGAGAAAG-3’. PCR conditions were as follows: 960C for 30 seconds, 29 cycles 
of 940C for 15 seconds, 600C for 1 minute and 680C for 10 minutes and a final extension of 
680C for 20 minutes. The resulting PCR products from the wildtype (4,226-bp) and the 
deletion (1,323-bp) allele were resolved and visualized in 1% agarose gels. 
 For genomic DNA extracted from FFPE tissues, we performed two different PCR 
reactions to assess the frequency of the wildtype and the deletion alleles. To genotype the 
wildtype allele, we used the forward primer 5-‘CCACCAATGGAAAAGGTTCA-3’ and the 
reverse primer 5’-CTGTCATTTCTCCCCACCAC-3’. The presence of the deletion allele was 
genotyped using the forward primer 5’-CCACCAATGGAAAAGGTTCA-3’ and the reverse 
primer 5’-GGCACAGCCTCTATGGAGAA-3’. PCR reactions involving these primers were 
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performed using the GoTaq Hotstart polymerase (Promega) with the following PCR 
conditions: 950C for 5 minutes, 40 cycles of 950C for 50 seconds, 580C for 50 seconds and 
720C for 1 minute and a final extension of 720C for 10 minutes. The resultant PCR products 
for the wildtype allele (362-bp) and the deletion allele (284-bp) were resolved in a 2% agarose 
gel. The identity of the PCR products were confirmed by sequencing. Note: Genotyping 
clinical samples by PCR were performed by Dr Ng King Pan and Mr Huang Weijie, both 
from Duke-NUS Graduate Medical School, Singapore.  
 
Assessment of population frequency: 
To infer the copy number of the BIM deletion polymorphism among HapMap 
samples, we used Affymetrix Genome-Wide Human SNP Array 6.0 intensity data 
downloaded from the HapMap221 homepage (http://snp.cshl.org/). We found two SNPs 
located within the deletion: SNP_A-4195083 and CN_173550. The raw intensities of these 
two SNPs were used to determine the copy number variation event using a Gaussian mixture 
model. Using this model, we predicted the copy number and inferred the presence or absence 
of the BIM deletion polymorphism in unrelated HapMap samples of European, African and 
Chinese/Japanese ethnicity. Subsequently, using the PCR method for genotyping patients 
from their peripheral blood, we genotyped samples from Chinese/Japanese individuals with 
the following PCR conditions: 960C for 30 seconds, 12 cycles of 940C for 15 seconds, 640C 
for 30 seconds, 680C for 5 minutes and 18 cycles of 940C for 15 seconds, 600C for 30 seconds, 
680C for 5 minutes and a final extension of 680C for 20 minutes. The results that we obtained 
from the genotyping were used to optimize the single nucleotide intensity cutoffs for genotype 
calling in the African and European samples. Because the number of HapMap samples were 
rather small, we have also genotyped a further 595 German, 600 Malay, 608 Chinese and 600 
Indian samples. Note: Assessment of population frequency was performed by Dr Axel 




Real-time RT-PCR  
Total cellular RNAs were extracted using the RNeasy Mini Kit (Qiagen). RNA was 
reverse transcribed using Superscript III First-Strand Synthesis System (Invitrogen) at a 
volume of 20 μl. Quantitative assessment of the target transcripts was assessed using the iQ5 
Multicolor Real-Time Detection System (Bio-Rad) with a reaction volume of 25 μl using the 
following conditions: 950C for 15 minutes, 40 cycles of 950C for 10 seconds, 590C for 20 
seconds and 720C for 30 seconds. Transcript levels of β-actin, TATA-binding protein (TBP) 
or exon 2A of BIM were used to normalize between samples. The following primers were 
used: BIM exon 3 (forward: 5’-CAATGGTAGTCATCCTAGAGG-3’; reverse: 5’-GACAAA- 
ATGCTCAAGGAAGAGG-3’), BIM exon 4 (forward: 5’-TTCCATGAGGCAGGCTGAAC-
3’; reverse: 5’-CCTCCTTGCATAGTAAGCGTT-3’), BIM exon 2A (forward: 5’-ATGGCA- 
AAGCAACCTTCTGATG-3’; reverse: 5’-GGCTCTGTCTGTAGGGAGGT-3’), hnRNP H 
(forward: 5’-ATTCAAAATGGGGCTCAAGGTAT-3’; reverse: 5’-GTGTCAGGACTATTT- 
GGACCAG-3’), hnRNP F (forward: 5’-AATTGTGCCAAACGGGATCAC-3’; reverse: 5’-
GTGTTTCCCTAGAGCCTTCTCA-3’), β-actin (forward: 5’-GGACTTCGAGCAAGAGAT- 
GG-3’; reverse: 5’-AGCACTGTGTTGGCGTACAG-3’), TBP (forward: 5’-CACGAACCA- 
CGGCACTGATT-3’; reverse: 5’-TTTTCTTGCTGCCAGTCTGGAC-3’).  
 
Luciferase assay to determine enhancer activity 
 The pGL4 luciferase reporter (a generous gift from Professor Ruan Yijun) was used to 
determine whether the 2,903-bp deleted fragment contains enhancer activity. The BIM 
promoter was amplified from genomic DNA derived from K562 cells using JumpStart 
RedAccuTaq LA DNA polymerase (Sigma) with the forward primer 5’-AGCCCAGCAAAC- 
TCGAGGGGTCCTAGCCAAATGCAGT-3’ and the reverse primer 5’-AGCGGCGCTGCC- 
ATGGGAGCTCCAACAAACTGCAGACC-3’ using the following PCR conditions: 960C for 
30 seconds, 34 cycles of 940C for 15 seconds, 630C for 1 minute and 680C for 1.5 minutes, 
followed by a final extension of 680C for 5 minutes. The PCR product generated was sub-
cloned into the XhoI and NcoI restriction enzyme sites in the pGL4 vector to create an 
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intermediate vector, pGL4-pro. Next, the 2,903-bp deleted fragment was amplified with the 
forward primer 5’-AGTGAGGTAGATCTGGCAGGCCTTTGCCCATGTT-3’ and the 
reverse primer 5’-TCTATGGAGTCGACCATGATGGTTCCCCAAAAAA-3’ using the 
following PCR conditions: 960C for 30 seconds, 35 cycles of 940C for 15 seconds, 630C for 1 
minute and 680C for 10 minutes, followed by a final extension of 680C for 20 minutes. The 
PCR product amplified was subcloned into BglII and HindII restriction enzyme sites in the 
pGL4-pro intermediate vector. K562 cells were nucleofected with the pGL4-pro reporters 
with or without the 2,903-bp deleted fragment. 24 hours post-nucleofection, the cells were 
treated with 1 μM imatinib. 15 hours later, luciferase activity was measured using the Dual-
Luciferase® Reporter Assay System (Promega). Note: The generation of the pGL4-pro 
reporters and the luciferase assay were performed by Dr Ng King Pan from Duke-NUS 
Graduate Medical School, Singapore.            
 
Minigene plasmids construction and assay for splicing changes 
I used the pI-12 vector (a generous gift from Professor Mariano Garcia-Blanco) to 
generate the WT and the DEL minigenes (Figure 7) for assessing whether the BIM deletion 
polymorphism has an effect on the splicing of BIM exon 3 and exon 4. Briefly, exon 4 of BIM 
and a 659-bp sequence upstream of exon 4, was amplified from KCL22 genomic DNA using 
PfuUltra® II Fusion HS DNA polymerase (Stratagene). The forward primer 5’-GCCGCTCG- 
AGTCTCTCCATGTGGTGTTTG-3’ and the reverse primer 5’-GCCGAAGCTTCCTCCTT- 
GCATAGTAAGCGTT-3’ were used for the PCR amplification. The PCR conditions were as 
follows: 950C for 2 minutes, 29 cycles of  950C for 30 seconds, 480C for 30 seconds, 720C for 
1 minute and a final extension of 720C for 7 minutes for 1 cycle. The PCR product generated 
was sub-cloned into the XhoI and HindIII restriction enzyme sites in the pI-12 vector to create 
an intermediate vector called pI-12-TW. Next, a stretch of sequence starting from 588-bp 
upstream of the intronic deletion until 683-bp downstream of exon 3 was amplified from 
KCL22 genomic DNA using the forward primer 5’-GCCGGATATCATGGAAGGAACTGA- 
CCTGGTG-3’ and reverse primer 5’-GCCGATCGATGTAGGAAACTGGGTGAATGGC-
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3’. The PCR conditions were as follows: 920C for 2 minutes, 10 cycles of  920C for 10 
seconds, 600C for 1 minute, 680C for 10 minutes and 25 cycles of 920C for 10 seconds, 650C 
for 1 minute, 680C for 10 minutes. Two PCR products (4,500-bp and 1,597-bp), with and 
without the BIM deletion polymorphism, were amplified since KCL22 is heterozygous for the 
deletion. These two PCR products were sub-cloned into the EcoRV and ClaI restriction 
enzyme sites in the pI-12-TW intermediate vector to obtain the WT and DEL minigenes. 
K562 and KCL22 cells were nucleofected with 1 μg of these minigenes. RNA was extracted 
from these cells 24 hours post-nucleofection. Reverse transcription was performed using the 
method described earlier. Real-time RT-PCR was employed to assess the expression of the U-
E3 and U-E4 transcripts. Expression levels of the U-E3 and U-E4 transcripts were normalized 
to the adenovirus exonic sequence, U. The following primers were used for real-time RT-
PCR: adenovirus exonic sequence, U (forward: 5’-CGAGCTCACTCTCTTCCGC-3’; reverse: 
5’-CTGGTAGGGTACCTCGCA-3’), U-E3 transcript (forward: 5’-CGAGCTCACTCTCTT- 
CCGC-3’; reverse: 5’-CTCTAGGATGACTACTGGTAGGGT-3’), U-E4 transcript (forward: 
5’-CGAGCTCACTCTCTTCCGC-3’; reverse: 5’- CCTCATGGAAGCTGGTAGGGT-3’). 
PCR conditions were as follows:  950C for 3 minutes, 40 cycles of 950C for 10 seconds, 590C 
for 14 seconds and 720C for 15 seconds.  
The WT minigene served as a template to generate the forward deletion constructs  
 
described in Figure 32. Primer sequences for these constructs are provided in Table 4. The  
 
PCR conditions were as follows: 950C for 2 minutes, 10 cycles of 950C for 20 seconds, 530C  
 
for 30 seconds, 720C for 3 minutes and 25 cycles of 950C for 20 seconds, 670C for 30 seconds  
 
and 720C for 3 minutes. All the forward deletion mutants described in Figure 32 were cloned  
 
by digesting PCR products with EcoRV and ClaI followed by ligation to the pI-12-TW  
 
















































































The WT minigene served as the template to generate the reverse deletion constructs  
 
described in Figure 32, whereas the Δ10, Δ10E or Δ10F minigene was used as the template to  
 
generate internal deletions, inversions or mutations within +2,582 to +2,903 of the BIM  
 
intronic deletion. Overlapping extension PCR was performed to generate these constructs.  
 
The method for performing overlapping extension PCR is illustrated in Figure 50. Briefly,  
 
sequences flanking the 5’end of the deletion were generated using a common forward primer,  
 
CPX, and a reverse primer, RX, where “X” denotes the primer number. Sequences flanking  
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the 3’ end of the deletion were generated with a common reverse primer, RPX, and a forward  
 
primer, UX, where “X” denotes the primer number. Primer sequences are provided in Table 5.  
 
The PCR conditions were optimized individually for each reaction to ensure that a single PCR  
 
product is generated. The resultant products were annealed by complementary base-pairing  
 
and amplified again using primers CPX and RPX. The final PCR product was sub-cloned into  
 
the pI-12-TW intermediate vector using the EcoRV and ClaI restriction enzyme sites. K562  
 
and KCL22 cells were nucleofected with 1 μg of the indicated minigenes. Using the method  
 
described earlier, real-time RT-PCR was performed to assess the expression of the U-E3 and  
 















Figure 50: Overlapping extension PCR. The red box and the red line denote sequences  
upstream of the deletion. The green box and the green line denote sequences downstream of  




 A different approach was used to create the Δ10E4 and the Δ10F3inv constructs.  
 
Briefly, the Δ10E4 construct was generated by using the Δ10E1 construct as a template and  
 
then create a PCR product that removes the second putative PTBP1 binding site using primers  
 
CP5, R15, U18 and RP1. The PCR product was sub-cloned into the pI-12-TW intermediate  
 
vector to obtain the pI-12-TW2 vector. The pI-12-TW2 vector was used as a template to  
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amplify a PCR product that has the third PTBP1 binding site removed by using primers CP5,  
 
R16, U19 and RP1. The final PCR product was sub-cloned into the pI-12-TW vector to obtain  
 
the Δ10E4 construct. To create the Δ10F3inv construct, I used the Δ10F minigene as a  
 
template and the primers CP6 and R20 to amplify a PCR product that replace 11-nt within the  
 
23-nt ISS. This product was sub-cloned into the pI-12-TW vector to obtain the pI-12-TW3  
 
vector. A second PCR was performed using the pI-12-TW3 vector as template and the primers  
 
U23 and RP1 to amplify a product that replaces the entire 23-bp ISS with a sequence that was  
 
































































































































































































































































Computational analysis to predict for cis-regulatory elements that regulate splicing 
 Prediction of cis-regulatory elements that regulate splicing was performed by using 
Sfmap171 (http://sfmap.technion.ac.il/), PESX172 (http://cubweb.biology.columbia.edu/pesx/), 
Splicing Rainbow173 (webpage no longer available), Human Splicing Finder174 
(http://www.umd.be/HSF/), and Spliceaid175 (http://www.introni.it/splicing.html). Analysis 
was performed by inputting the RNA sequences into the programs. Regulatory elements that 
were predicted by more than one program were selected for further functional analysis. 
 
RT-PCR and sequencing of BIM splice variants 
To determine whether the BIM deletion polymorphism resulted in the generation of 
novel BIM splice variants, I performed RT-PCR and sequenced all BIM transcripts that were 
amplified. Total cellular RNA extraction and reverse transcription was performed using the 
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method that was described above. Two different pairs of primers were used because BIM exon 
3 and exon 4 are mutually exclusive. To amplify all splice variants that harbor exon 2 and 
exon 5, I used the forward primer 5’-ATGGCAAAGCAACCTTCTGA-3’ and the reverse 
primer 5’-TCAATGCATTCTCCACACCA-3’. PCR was performed using the HotStarTaq 
DNA polymerase (Qiagen) using the following conditions: 950C for 15 minutes, 35 cycles of 
940C for 30 seconds, 570C for 30 seconds, 720C for 1 minute and 1 cycle of 720C for 10 
minutes. To amplify exon 3-containing transcripts, I used the forward primer 5’-TGACTCTC- 
GGACTGAGAAACG-3’ and the reverse primer 5’-CCAAAGCACAGTGAAAGATCA-3’. 
The PCR conditions were as follows: 950C for 15 minutes, 35 cycles of 940C for 30 seconds, 
550C for 30 seconds, 720C for 30 seconds and 1 cycle of 720C for 10 minutes. The PCR 
products were then resolved in a 2% agarose gel. All observable PCR products were excised 
and cloned into pJET1.2/blunt vector (Fermentas) before they were sent for sequencing.  
 
Protein extraction and western blot 
Whole cell lysates were obtained using RIPA lysis buffer (Millipore). Lysis was 
performed on ice for 20 minutes in the presence of protease and phosphatase inhibitors 
(Roche). Protein estimation was performed using the Bradford assay (Bio-Rad Laboratories). 
The samples were resolved by gel electrophoresis in a 11% polyacrylamide gel. Once 
electrophoresis was completed, the gel was rinsed in water before the proteins were electro-
blotted onto a polyvinylidene difluoride membrane. When transfer was completed, the blot 
was blocked for one hour in 5% (w/v) non-fat milk in Tris buffered saline-Tween (TBST) 
(100 mM Tris-base, 154 mM NaCl, 0.1% (v/v) Tween 20, pH 7.4). The following primary 
antibodies were used to probe the membrane: CrkL (#3182), pRPS6 (#2211), RPS6 (#2317), 
BIM (#2819), caspase 3 (#9662), cleaved caspase 3 (#9661), pSTAT5A (#9359), STAT5A 
(#9310), PARP (#9542), p-EGFR (#2234), GAPDH (#2118) (all from Cell Signaling 
Technology), FLAG (F1804, Sigma), β-actin (#AC-15, Sigma),  β-catenin (610154, BD 
Biosciences), PTBP1 (32-5000, Invitrogen), hnRNP H (ab10374, Abcam), hnRNP F 
(ab50982), hnRNP C (ab10294, Abcam) and KHSRP (A302-021A, Bethyl Lab). Antibodies 
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specific against BIMγ were generated by a commercial company (Open Biosystems).  All 
primary antibodies were diluted at 1:1000 except for β-actin (1:5000)  in TBST with 5% (w/v) 
non-fat milk. Three washes in TBST were performed after primary antibody incubation before 
the appropriate horse radish peroxidase-conjugated secondary antibodies (Santa Cruz 
Biotechnology) at a dilution of 1:10,000 were used to probe the membrane. The membrane 
was visualized using the Western Lightning chemiluminescence reagent (PerkinElmer).   
 
Trypan blue exclusion assay 
5 x 105 K562, KYO-1, NCO2 and KCL22 cells were seeded in triplicates and treated 
with 1 μM imatinib. Viable cell count was determined every 24 hours for 120 hours by trypan 
blue exclusion. 
 
BIM expression plasmids and siRNAs 
I cloned the cDNA of the various BIM splice variants (BIMEL, BIML, BIMS and BIMγ; 
generous gifts from Dr Aimé Vazquez) into the pcDNA3-FLAG3 vector (a generous gift from 
Dr Koji Itahana) via EcoRI and XhoI restriction enzyme sites. The cloning primers used were 
described in Table 6. CML cell lines were nucleofected with 5 μg of each plasmid using the 
Cell Line Nucleofector Kit V (Lonza).  
siRNAs were synthesized either from Integrated DNA Technologies or from Ambion. 
The siRNA sequences used were as follows, control siRNA: GGUCCGGCUCCCCCAAAU- 
C, BIMγ siRNA 1: CCACCAUAGUCAAGAUACA, BIMγ siRNA 2: CAGAACAACUCAA- 
CCACAA, PTBP1 siRNA 1222: CUUCCAUCAUUCCAGAGAA, PTBP1 siRNA 2: CAAAG- 
CCUCUUUAUUCUUU, PTBP1 siRNA 3: CAGUUUACCUGUUUUUAAA, hnRNP H 
(siH1): GAAGCAUACUGGUCCAAAU, hnRNP H (siH2): GGAUUUGGGUCAGAUAGA- 
U, hnRNP F (siF1): GCAGCACAGAUAUAUAGAA, hnRNP F (siF2): CGACCGAGAAC- 
GACAUUUA, hnRNP C (si1): CAACGGGACUAUUAUGAUA, hnRNP C (si2): GAUGA-  
AGAAUGAUAAGUCA, hnRNP C (si3): ACACUCUUGUGGUCAAGAA. Knockdown 
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experiments were performed with the appropriate siRNAs on 1 x 106 K562 or KCL22 cells 
using the Cell Line Nucleofector Kit V (Lonza).  
 
Target cDNA Primer sequence 
Exon 4-containing BIM 
transcripts 












Table 6: Primers for cloning BIM splice variants. 
 
Annexin V staining 
Annexin V staining was performed using a kit (BD Biosciences) to measure the 
percentage of apoptotic cells. Briefly, cells were washed twice with phosphate-buffered saline 
and then resuspended in binding buffer (0.1 M HEPES, 1.4 M NaCl, 25 mM CaCl2, pH 7.4). 
Subsequently, Annexin V conjugated to FITC was added to the cells. The cells were 
incubated at room temperature in the dark for fifteen minutes before they were analyzed by 
flow cytometry.   
 
Measurement of protein stability 
To assess the stability of BIMγ and BIML, I nucleofected 1 x 106  K562 cells with 
plasmids expressing FLAG-tagged BIMγ or BIML. 44 hours post-nucleofection,  these cells 
were treated with the protein translation inhibitor, cycloheximide, at 50 μg/ml. The cells were 
harvested at several time points (0, 0.5, 1, 3, 5, 7 hours) post-treatment. The stability of 
FLAG-tagged BIMγ and BIML was determined by Western blot using antibodies specific 
against the FLAG epitope.  
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Generating cell lines harboring the BIM deletion polymorphism using ZFNs 
The ZFNs were synthesized by Sigma-Aldrich CompoZr™ ZFN Technology which 
consisted of the following binding (underlined) and cleavage sites (italics): 5’-CCTTCCCTG- 
GAA-ctggga-ATAGTGGGTGAGATAGTG-3’. For the repair template, it contained only the 
two flanking homology arms with the 2,903-bp intronic sequence removed. To generate the 
repair template, the forward primer 5’-CATAAATACCACAGAGGCCCACAGC-3’ and the 
reverse primer 5’-CCCTCGAAGACACCTCTATTGGGAGGC-3’ was used to amplify the 
two flanking homology arms from KCL22 genomic DNA. The 1,362-bp PCR product 
amplified was sub-cloned into the pCR®-Blunt II-TOPO® vector (Invitrogen). The plasmid 
with the correct sequences was confirmed by sequencing.  
The repair template and the mRNA transcripts that express the ZFNs were 
nucleofected into K562 cells using the Cell Line Nucleofector Kit V (Lonza). To create PC9 
cells that harbor the BIM deletion polymorphism, PC9 cells were seeded at a density of 2 x 
105 cells per well in a 6-well plate. After recovering overnight, these cells were transfected 
using Fugene HD (Promega) with 6 μg of repair template and 0.6 μg of plasmids expressing 
ZFNs. To isolate subclones that harbor the BIM deletion polymorphism, dilution cloning was 
performed on ZFN-edited K562 and PC9 cells 72 hours post-transfection. Dilution cloning 
was performed by seeding the transfected cells at a density of 0.5 cells/ 200 μl media in 96-
well plates. Subclones that can proliferate were harvested a few weeks later and the genomic 
DNA was isolated using the DNeasy Mini Kit (Qiagen). To screen for clones that harbor the 
BIM deletion polymorphism, PCR was performed using the forward primer 5’-GGCCTTCA- 
ACCACTATCTCAGTGCAATGG-3’ and the reverse primer 5’-GGTTTCAGAGACAGAG- 
CTGGGACTCC-3’. Note: The generation of cell lines that harbor the BIM deletion 






ELISA-based DNA fragmentation assay 
The presence of mono- and oligo-nucleosomes in apoptotic cells was detected by 
using the Cell Death Detection ELISA (Roche), following the manufacturer's instructions.  
Genome-edited K562 and PC9 cells were seeded at a density of 2 X 105 cells/ml and 5 X 104 
cells, respectively. 24 hours post-treatment, 0.5 ml of cells were used for the ELISA-based 
assay. Note: ELISA-based DNA fragmentation assay was performed by Dr Ko Tun Kiat 
from Duke-NUS Graduate Medical School, Singapore.  
 
RNA pull-down assay and mass spectrometry analysis 
 Nuclear extract was obtained from 10 x 106 K562 cells using the NE-PER Nuclear 
and Cytoplasmic Extraction Reagents (Thermo Scientific). The 10F, 10F4 and 10F3inv RNAs 
were synthesized by Integrated DNA Technologies. Each RNA (200 pmole) was biotinylated 
using the Pierce™ Magnetic RNA-Protein Pull-Down Kit (Thermo Scientific) according to 
the manufacturer’s instructions. After labeling, the labeled RNAs were bound to streptavidin 
magnetic beads and then incubated with 100 μg of K562 nuclear extract for one hour at 40C. 
The RNA-bound protein complexes were eluted using 50 μl of biotin elution buffer. Gel 
electrophoresis using a 10% polyacrylamide gel was performed to separate the eluted proteins.  
 Silver staining was performed to visualize the gel. Briefly, the gel was washed twice 
for fifteen minutes in 50% methanol, followed by a single wash in 5% methanol. Next, the gel 
was washed with water containing 60 μM DTT and then incubated with 0.1% (w/v) silver 
nitrate for fifteen minutes. The gel was washed twice twice with water before it was incubated 
with developing solution which contains 3% (w/v) sodium carbonate and 0.05% (v/v) 
formaldehyde. The gel was shaken at 80 rpm for bands to appear. When bands of the desired 
intensity appeared, solid citric acid was added to stop the reaction. The gel was washed three 
times with water for fifteen minutes each before excising desired protein bands. The excised 
protein bands were sent to the Nanyang Technological University (Singapore) for mass 




Statistical analysis  
 Logistic regression analysis on each cohort (Singapore and Malaysian, Japanese), as 
well as the combined cohort, was carried out to assess the association between the BIM 
deletion polymorphism and clinical resistance to imatinib. We have also adjusted for age 
differences due to the comparable magnitude of age differences observed within each cohort.  
 To assess the repercussions of the BIM deletion polymorphism on NSCLC patients 
treated with EGFR inhibitors, we performed a Kaplan-Meier analysis on patients with and 
without the BIM deletion polymorphism. The p-value of the Kaplan-Meier test was calculated 
using the log-rank test. Patients who discontinued from therapy with EGFR inhibitors due to 
adverse side effects were not included in our analysis.  Note: Statistical analysis was 
performed by Assistant Professor John C Allen, Dr Ng King Pan and Ms Sheila Soh, all 
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